The Board of Directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to announce the audited consolidated results of the Company and its subsidiaries (together, the “Group”) for the year ended 31 December 2025.…
The Board of Directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”) is
pleased to announce the audited consolidated results of the Company and its subsidiaries (together, the
“Group”) for the year ended 31 December 2025.
FINANCIAL HIGHLIGHTS
(in RMB’000, unless otherwise stated)
2025
2024
Change
Revenue by business units:
Finished drugs
Bulk products
Functional food and others
20,583,729
3,656,972
1,765,279
23,736,157
3,583,163
1,689,934
-13.3%
+2.1%
+4.5%
Total revenue
26,005,980
29,009,254
-10.4%
Profit attributable to shareholders of the Company
Reported
Underlying (Note)
3,882,108
3,534,326
4,328,035
4,682,909
-10.3%
-24.5%
Earnings per share (RMB cents)
Based on reported profit attributable to shareholders
of the Company
— Basic
— Diluted
33.98
33.98
36.87
36.87
-7.8%
-7.8%
Final dividend per share (HK cents)
15.00
10.00
+50.0%
Full-year dividend per share (HK cents)
29.00
26.00
+11.5%
Note: Underlying profit attributable to shareholders of the Company, a non-HKFRS Accounting Standards
measure, represents profit attributable to shareholders of the Company before taking into account fair
value changes on financial assets measured at fair value through profit or loss (“FVTPL”), and employee
share-based compensation expense. A reconciliation between reported and underlying profit is provided on
page 39 of this announcement.
–1–
CHAIRMAN’S STATEMENT
Results
In 2025, the reported profit attributable to shareholders of the Company was RMB3,882 million,
compared with RMB4,328 million in 2024. The underlying profit attributable to shareholders of the
Company for the year (excluding fair value changes on financial assets measured at fair value through
profit or loss and employee share-based compensation expenses) was RMB3,534 million, compared
with RMB4,683 million in 2024.
Dividend and Share Buy-Backs
The Board recommended a final dividend of HK15 cents per share for 2025. Subject to the approval of
shareholders of the Company at the forthcoming annual general meeting, the proposed final dividend
will be paid on Wednesday, 15 July 2026 to shareholders of the Company whose names appear on
the register of members on Monday, 29 June 2026. Together with an interim dividend of HK14 cents
per share, the full-year dividend for 2025 amounted to HK29 cents per share, an increase of 11.5% as
compared to 2024.
In 2025, the Group utilised a total of approximately HK$300 million to repurchase and cancel
64,300,000 shares in aggregate.
Industry Review
In 2025, jointly driven by the combined impetus of deepened reform and precision regulation in
China’s pharmaceutical industry, the industry entered a critical transition period for high-quality
development with both opportunities and challenges and exhibited a distinct shift, leaping from scaledriven growth to value-driven innovation. China achieved a historic breakthrough in the review and
approval of innovative drugs in 2025, with a total of 76 innovative drugs approved for marketing
during the year, hitting a record high.
On 30 June 2025, the National Healthcare Security Administration and the National Health
Commission of the PRC jointly issued the Circular on Several Measures to Support the High-Quality
Development of Innovative Drugs (《支持創新藥高質量發展的若干措施》). This policy improved
the full-chain support system for innovative drugs and established systematic support for the entire
life cycle of innovative drugs in aspects including Research and Development (“R&D”) support,
accelerated market access, relaxed assessment requirements and diversified payment methods.
The national centralised drug procurement policy has been continuously optimised, with its rules
constantly refined. The 11th batch of national centralised procurement as well as the successive
procurement for drugs covered in the 1st to 8th batches of centralised procurement have been advanced
in succession. The relevant measures adhere to the principles of “ensuring stable clinical supply,
upholding product quality, preventing collusive bidding and curbing irrational internal competition”,
aiming to safeguard enterprises’ enthusiasm for innovation, strengthen full-chain quality supervision,
optimise the volume reporting mechanism and bidding rules, and check irrational competition in the
industry.
–2–
Meanwhile, 2025 was widely regarded as a pivotal year of the “value upgrade” for the global business
development expansion of China’s innovative pharmaceuticals. The total value of out-licensing deals
surpassed US$135.6 billion across 157 transactions. In this year, the industry completed a crucial
transition from “scale expansion” to “value deepening” and from “product export” to the “technology
and standard export”.
Business Review
In 2025, the Group closely followed the trajectory of industry development and aligned with policy
guidance. We focused on core businesses and advanced management reforms to build a flatter, more
efficient organisational structure. By adhering to a dual-engine strategy driven by innovation and
internationalisation, the Group consolidated its foundation for steady growth amidst a complex and
volatile market environment, providing robust support for strategic breakthroughs.
The Group continues to enrich its product matrix and enhance product competitiveness. A series of
major products and new indications approved for marketing between 2024 and 2025 have provided
the Group with sustained growth momentum. Mingfule (明復樂 ®), an innovative drug in the field
of cerebrovascular diseases, has continued and strengthened the Group’s competitive edge in this
area. Its synergistic effect with NBP (恩必普®) further consolidates the Group’s leading position in
cerebrovascular disease treatment. The successful launches of Enshuxin (恩舒幸®) (enlonstobart for
injection), Enyitan (恩益坦®) (the first omalizumab biosimilar), the hypoglycemic drug Prusogliptin
Tablets, and Meloxicam Nanocrystal Injection have driven a more balanced layout for the Group’s
portfolio in autoimmune diseases, endocrine metabolism, and oncology, significantly enhancing future
growth potential.
The Group remains steadfast in the belief that R&D innovation is the core competitiveness of a
pharmaceutical enterprise and the key to resolving “bottleneck” challenges and driving high-quality
industry development. Against the background of continuous policy support for innovation in 2025,
the Group increased investment in R&D. Leveraging our eight innovative R&D platforms, we adhere
to a clinical-need-oriented approach, systematically advancing the research and clinical development
of innovative drugs. In 2025, the Group obtained 14 manufacturing approvals and 73 clinical trial
approvals, along with 5 Breakthrough Therapy Designations. Among these are several major products
with global patents and substantial market value.
The Group has been promoting the implementation of its innovative pipeline, strengthening
breakthroughs in key core technologies. Leveraging its two State Key Laboratories, it focuses on
applied basic research and overcoming common technological challenges while actively exploring
cutting-edge technologies such as cell therapy and nucleic acid therapy, advancing the R&D of
products such as the autologous CAR-T drug candidate SYS6055, therapeutic tumor vaccines,
and small nucleic acid drugs. These efforts further optimise the layout of its innovative products,
demonstrating the Group’s robust innovative R&D capabilities. Additionally, on the digital front, the
Group actively deepens the application of AI technology in drug R&D and expands AI-assisted R&D
platform. By empowering innovation with technology and accelerating intelligent transformation, the
Group continuously enhances its R&D efficiency and its ability to transform outcomes into success.
–3–
In terms of internationalisation, the Group is steadily advancing its global strategy and accelerating its
overseas market expansion. With a focus on the European and American markets, the Group promotes
the project initiation and expansion of high-value-added products including high-end complex
injectable preparations, monoclonal/bispecific antibody biologics and inhalants. The Group is actively
promoting the marketing authorisation of liposomal amphotericin B for injection in the United States
and the European Union, striving to overcome barriers in high-end overseas markets. Meanwhile, the
Group continues to deeply cultivate markets along the “Belt and Road”, advancing product registration
and sales in countries such as Singapore, Thailand, Russia, and Vietnam. By establishing in-depth
cooperation with local strategic clients and advancing the construction of an academic promotion
platform in Southeast Asia, the Group persistently enhances the contribution of its overseas business.
In terms of business development, since early 2025, the Group has completed five out-licensing
deals, with an aggregate contract value of US$28.21 billion. This fully demonstrates the Group’s
international innovation capabilities and technological strength, significantly enhancing its
international visibility and industry influence, and laying a solid foundation for expanding overseas
markets and deepening international cooperation.
The Group attaches great importance to Environmental, Social and Governance (ESG) initiatives,
adhering to the principles of green development, harmonious coexistence and sustainable operations. It
continuously improves its corporate governance system and actively fulfills its social responsibilities.
The Company has maintained an A rating in the MSCI ESG Ratings for five consecutive years.
Outlook
We strongly believe that R&D innovation is the core competitiveness of pharmaceutical enterprises.
Looking forward, the Group will continue to leverage the core strengths of its eight innovative
R&D platforms, make every effort to advance the realisation of key pipelines, and seize critical
R&D milestones in 2026. Adhering to clinical demand as the guiding principle, we will actively
deploy new targets and expand into emerging sectors including gene therapy, cell therapy and
metabolomics. Meanwhile, we will further deepen the integration of AI technology in drug discovery
and development. Leveraging our AI-driven drug discovery platform, we will also accelerate the
identification and optimisation of innovative drug candidates, enhance R&D efficiency and precision,
and empower innovation through technology. This will drive the Group’s transformation into an
intelligent pharmaceutical enterprise, thereby comprehensively elevating its R&D capabilities and
accelerating the translation of research outcomes.
In terms of internationalisation, building upon the solid foundation laid by major licensing and
collaborations in 2025, we will deepen our global strategy and achieve an upgrade from “overseas
expansion for product” to “overseas expansion for platform and technology”. We will also strengthen
strategic collaborations with world-leading pharmaceutical companies, further accelerate outlicensing arrangements, improve the operational efficiency of overseas businesses, enhance synergy
with local partners, and expand product registration and commercial networks. By advancing the
internationalisation process of our products, we will deliver more innovative results to the global
market and demonstrate the Group’s capabilities and influence in pharmaceutical innovation.
–4–
2026 marks the opening year of the 15th Five-Year Plan. As the core arena and breakthrough point
for the future industries such as biomanufacturing, the biopharmaceutical section faces significant
strategic opportunities. The Group will uphold its core philosophy of “All for good medicine,
all for mankind’s health”, and implement its development strategy of “Innovation, Growth and
Sustainability”. We will promote the deep integration of industrial and technological innovation,
supporting China’s pharmaceutical industry to align with international standards on its path of highquality development.
Appreciation
I would like to take this opportunity to express my sincere gratitude to all staff for their dedication and
diligence. I would also like to extend my heartfelt thanks to all our shareholders, business partners and
customers for their enduring trust and strong support to the Group over the years!
CAI Dong Chen
Chairman
25 March 2026
–5–
MANAGEMENT DISCUSSION AND ANALYSIS
Overview
The Group is an innovation-driven comprehensive pharmaceutical enterprise integrating R&D,
manufacturing and sales. With the corporate mission of “All for good medicine, all for mankind’s
health”, we are committed to developing innovative products to address unmet clinical needs and
provide innovative treatment options for patients.
“Leading Innovation and Creating an Excellent CSPC” is the core vision of CSPC people.
Under the leadership of the Chairman and guided by the dual-engine strategy of “Innovation and
Internationalisation”, the Group continues to increase its investment in R&D and strengthen talent
acquisition and team building to enhance its domestic and international competitiveness, which
provides a strong driving force for the long-term sustainable development of the Group.
The Group has an internationalised R&D team with more than 2,000 professionals and R&D centers
located in Shijiazhuang, Shanghai, Beijing and the United States (the “U.S.”), focusing on key
therapeutic areas such as oncology, psychiatry and neurology, cardiovascular, immunology and
respiratory, digestion and metabolism, and anti-infectives. Meanwhile, the Group seeks to strengthen
platform advantages by building eight core technology platforms to raise the technical barriers to
entry, thereby taking the lead in establishing an industry-leading AI drug discovery technology
platform and a globally leading delivery technology system, creating a significant competitive edge
through differentiation.
The Group has achieved rapid advancements in innovative drug R&D, yielding a continuous stream
of innovative achievements. In the field of large molecules, the Group has established a leading
antibody-drug conjugate (ADC) platform, with more than 10 ADC drug candidates having entered
various clinical stages, and took the initiative to out-license ADC drugs targeting Nectin-4 and other
targets to overseas pharmaceutical companies. In the field of small molecules, the Group took the
lead in using AI technology for design and screening. The small molecules we developed, such as
Lp(a) and MAT2A, have been successfully out-licensed to international pharmaceutical companies
like AstraZeneca, sparking a wave of AI-driven small molecule drug R&D domestically. In the
field of cell therapy, the Group was the first in the world to advance LNP/mRNA-based CAR-T
therapy into clinical trials, with clinical studies targeting indications such as multiple myeloma,
lupus erythematosus and myasthenia gravis. In terms of long-acting drug delivery technology, an in
situ gel platform has been created by the Group to advance long-acting agents such as octreotide,
semaglutide and leuprorelin into clinical trials. In terms of nano-formulation, the Group invented
new albumin nano-delivery technology. In a head-to-head comparative study, paclitaxel (albuminbound) II it developed demonstrated better efficacy and safety profiles compared to the paclitaxel
albumin preparation. Docetaxel, sirolimus and other albumin preparations have also shown favorable
safety profiles and survival benefits, and have all entered the stage of registrational clinical trials.
Our R&D of small nucleic acid drugs ranks among the top tier in China, projects such as PCSK9 and
AGT have successively entered clinical trials, the development of mRNA vaccines has expanded from
–6–
preventive vaccines to therapeutic vaccines, and the clinical trials of a number of projects such as the
VZV mRNA vaccine and the HPV therapeutic mRNA vaccine are being accelerated. As a whole, the
Group has established eight innovative technology R&D platforms, encompassing nano-formulation,
messenger RNA (mRNA), small interfering RNA (siRNA), antibody/fusion protein, cell therapy, and
antibody-drug conjugates (ADC), which provide a solid technological foundation for the discovery and
translation of innovative drugs.
The Group actively fulfilled its social responsibilities and achieved remarkable results in safeguarding
public health and enhancing industry competitiveness. At a time when domestic enterprises had not yet
focused on innovative drugs, the Group demonstrated foresight by strategically deploying resources
to successfully develop NBP (恩必普®), the first Class 1 innovative drug in the stroke field, which
has benefited more than 40 million patients. In order to solve the common problem of bone marrow
suppression in tumor chemotherapy, the Group researched and launched Jinyouli (津優力®), the first
domestically produced long-acting white blood cell booster formulation. The Group independently
developed China’s first COVID-19 mRNA vaccine in response to the national call during the
COVID-19 pandemic, achieving a breakthrough in mRNA vaccines in China.
In order to further meet the emergency needs of stroke patients, the Group developed Mingfule,
China’s first thrombolytic drug that can be administered in ambulances, successfully breaking the
technological monopoly of foreign countries. The Group took the lead in the R&D and launched
several nano-formulations, such as Duoenyi (多恩益®) and Anfulike (安復利克®), which effectively
reduced the medication cost, enhanced therapeutic efficacy, and benefited numerous patients. Our
independently developed nanodrug Duoenda can significantly prolong patient survival, changing the
long-standing situation of ineffective treatments for peripheral T-cell lymphoma. These achievements
underscore the Group’s patient-centric R&D philosophy and strong sense of social responsibility.
Years of sustained investment and outstanding performance have earned the Group extensive
recognition from the government, regulatory authorities and various sectors of society. The Group has
been recognised as a “National Innovative Enterprise” and a “National Enterprise Technology Center”,
with two national key laboratories, including the “National Key Laboratory for New Pharmaceutical
Preparations and Excipients” and the “National Engineering Laboratory for Chiral Drugs”. In addition,
the Group has led the establishment of the “National Nano Intelligent Manufacturing Industry
Innovation Center”, the only national-level innovation platform in the nano-industry in collaboration
with several renowned enterprises.
In terms of scientific and technological innovation evaluation, the Group has won the Second Prize
of the National Award for Science and Technology Progress four times, the China Grand Awards for
Industry twice and the China Patent Gold Prize three times. The Group has ranked among the global
top 25 pharmaceutical pipeline by Citeline for three consecutive years, reaching 19th position this year
and up five places from the previous year. This demonstrates the Group’s increasing R&D capabilities
and international competitiveness.
–7–
The Group’s R&D achievements (such as Mingfule, NBP and mRNA vaccines) have been published
multiple times in the top international journals such as The New England Journal of Medicine and
The Lancet, and have successfully rewritten the Chinese or even international diagnosis and treatment
guidelines. Several projects, including mitoxantrone liposomes, EGFR ADC, EGFR monoclonal
antibody, SYH1813 and docetaxel (albumin-bound) have been repeatedly invited for oral presentations
at international academic conferences such as ASCO, ESMO and ASH, receiving good international
response and wide attention from the industry. Furthermore, EGFR ADC, Nectin-4 ADC, CD20/CD47,
HER2 bispecific antibody, sirolimus albumin preparation and other products developed by the Group
have also been granted a number of Breakthrough Therapy Designations and Fast Track Designation
by Chinese and the U.S. regulatory authorities.
At present, the Group has more than 200 innovative drugs and preparations under R&D, including
over 90 large molecule drugs, over 60 small molecule drugs, over 50 new preparations and more than
160 clinical trials in progress, some of which have promising market prospects and are significantly
superior to existing therapies in efficacy and safety. Representative products in several key areas are
as follows:
In the field of breast cancer, our products include paclitaxel (albumin-bound) II for the treatment
of advanced breast cancer (head-to-head comparative studies have demonstrated superior efficacy
and safety versus Paclitaxel for Injection (Albumin Bound)); KN026 in combination with docetaxel
(albumin-bound) for the first-line and neoadjuvant treatment of HER2-positive breast cancer; sirolimus
albumin preparation (granted Breakthrough Therapy Designation) in combination with fluvestrant for
the second-line treatment of HR-positive/HER2-negative breast cancer; and JSKN003 for the treatment
of HER2-positive and HER2-low expression breast cancer in second-line and beyond.
In the field of lung cancer, our products include EGFR ADC for the treatment of EGFR mutated
non-small cell lung cancer (NSCLC) in second-line and beyond (granted Breakthrough Therapy
Designation and fast track designation); JMT101 in combination with ohitinib for the first-line
treatment of EGFR classical mutated NSCLC.
In the field of gastrointestinal tumors, our products include KN026 for second-line treatment of HER2positive gastric cancer (granted Breakthrough Therapy Designation); cimetinib tablets for secondline treatment of esophageal squamous cell carcinoma; and docetaxel (albumin-bound) for advanced
pancreatic cancer and second-line treatment of gastric cancer (phase II clinical trial results were
superior to standard treatment) and others.
–8–
In the cardiovascular and metabolic field, our products include TG103 for the treatment of diabetes
and obesity; prusogliptin and metformin extended-release tablets and prusogliptin, dapagliflozin and
metformin extended-release tablets for the treatment of diabetes; valsartan maleate levamlodipine
tablets for the treatment of hypertension, and others.
The successive market launches of the aforementioned products will effectively address unmet
clinical needs and benefit many patients, while also fully demonstrating the core value of the Group’s
product pipelines, enhancing the Group’s competitiveness in the industry, and providing continuous
momentum for the Group’s development. At the same time, this also signifies that the Group has
quickly passed the painful period of transformation and is steadily moving towards a path of long-term
and sustainable development.
In terms of internationalisation, driven by innovative R&D as our engine, the Group is advancing its
global strategic deployment to build a worldwide pharmaceutical value ecosystem. In terms of global
R&D positioning, with the strategy of “dual China-US regulatory submission”, we initiate a number
of multi-center clinical trials across Europe and America. The Group has established R&D systems
and quality platforms that meet international standards, laying a solid foundation for global product
launches. Regarding overseas expansion of innovative products, Nectin-4 ADC, ROR-1 ADC, LP(a)
small molecules and other products independently developed by the Group have been out-licensed
overseas. Since the beginning of 2025, the Group has completed five out-licensing projects. Notably,
in June 2025 and January 2026, the Group entered into two separate strategic R&D collaborations
with AstraZeneca, an internationally renowned pharmaceutical company, on the AI small molecule
platform, long-acting delivery technology platform, and AI-enabled peptide drug platform,
accelerating the transformation of China’s innovative pharmaceutical enterprises from “product
export” to “technology platform export” and progressively elevating from “technology licensor” to
“global co-developer”.
The Group possesses strong commercialisation capabilities and has currently established a professional
sales team of over 10,000 individuals, extensively covering medical institutions and retail pharmacy
network across the country. We are actively expanding into lower-tier markets and developing the
potential of county-level markets to provide high-quality drugs at the grass roots. This established
sales team and extensive commercialisation experience provide strong safeguards for the sales
performance of the innovative drugs to be launched on the market.
The Group will keep driving the high-quality development of China’s pharmaceutical industry through
continuous innovation and solid commercialisation capabilities, thereby benefiting more patients.
–9–
BUSINESS REVIEW
Finished Drug Business
2025 was a pivotal period of deepening reforms in the pharmaceutical industry, during which the
Group proactively addressed market challenges brought about by the full rollout of centralised
procurement policies. Despite significant price adjustments for core products such as Duomeisu
and Jinyouli, which resulted in temporary pressure on revenue from finished drug business, we
achieved encouraging progress through forward-looking strategic planning and an innovation-driven
development approach. The key initiatives and business reviews are as follows:
Advancing international expansion to unleash the global potential of our innovation-value
Aligned with the “Innovation + Internationalisation” dual-driven strategy, the Group leverages
its rich innovation assets to deepen collaborations with international innovative pharmaceutical
enterprises. Through diversified approaches including proprietary development, out-licensing and
R&D collaborations, we are actively expanding into overseas markets and accelerating the translation
and commercialisation of innovative outcomes globally. This strategy has already yielded notable
results. Since the beginning of 2025, the Group has concluded 5 out-licensing deals with a contract
value reaching US$28.21 billion. This not only injects new growth momentum into our finished drug
business but also demonstrates the high level of recognition and trust from the global pharmaceutical
industry places in the Group’s innovation pipeline. In the future, we will continue to cultivate our outlicensing business, with the goal of developing it into one of the stable, recurring revenue stream of
the Group.
Accelerating the advancement of the innovative R&D pipeline to consolidate the core product
competitiveness
The Group continues to increase investment in innovative R&D, consistently guided by the unmet
clinical needs of patients, focusing on the development of products with differentiated competitive
advantages and accelerating the market launch of new products. Simultaneously, we are actively
exploring and positioning ourselves in cutting-edge technologies to enhance the long-term competitive
advantages of our pipeline, thereby providing robust support for future performance growth.
Proactively addressing market challenges and enhancing channel deployment and academic
promotion
The Group continuously optimises its market strategies by intensifying hospital channel penetration,
expanding into lower-tier markets, and broadening the retail networks, thereby significantly enhancing
product coverage and accessibility. On the academic front, we focus on addressing clinical pain points,
expanding indications and clinical application scenarios, while strengthening professional academic
promotion to deepen the understanding of our products’ clinical value, thereby boosting market
penetration and brand influence of our products.
– 10 –
Looking ahead, the pharmaceutical industry is entering a new phase of high-quality development.
The Group will proactively capitalise on opportunities arising from industry transformation. In
an increasingly complex and volatile market environment, we will further strengthen our core
competitiveness to achieve sustainable high-quality development and strive to become a globally
leading pharmaceutical enterprise.
The finished drug business recorded a revenue of RMB20,584 million (including licence fee income of
RMB1,789 million) throughout the full year of 2025, representing a decrease of 13.3% as compared to
the previous year. The analysis of revenue from finished drug business is as follows:
2025
(RMB’000)
2024
(RMB’000)
Change
By Therapeutic Area
Nervous system
Oncology
Anti-infectives
Cardiovascular
Respiratory system
Digestion and metabolism
Others
7,817,136
2,200,925
3,323,959
1,833,883
1,222,905
943,326
1,452,894
9,644,960
4,399,890
4,086,264
2,079,144
1,199,216
1,050,658
1,258,194
-19.0%
-50.0%
-18.7%
-11.8%
+2.0%
-10.2%
+15.5%
Sales of goods
Licence fee income
18,795,028
1,788,701
23,718,326
17,831
-20.8%
+9,931.4%
Total revenue
20,583,729
23,736,157
-13.3%
Nervous System
Major products include NBP (恩必普®) (butylphthalide soft capsules/injection), Mingfule (明復樂®)
(recombinant human TNK tissue-type plasminogen activator for injection), Oulaining (歐來寧 ® )
(oxiracetam capsules/oxiracetam for injection), Shuanling (舒安靈 ® ) (pentoxifylline extendedrelease tablets/injection), Enxi (恩悉 ®) (pramipexole dihydrochloride tablets), Oushuan (歐舒安 ®)
(paliperidone extended-release tablets) and Enliwei (恩理維®) (lacosamide injection/tablets), etc.
•
NBP (恩必普®)
NBP is China’s first Class 1 innovative chemical drug with independent intellectual property
rights in the field of cerebrovascular diseases. It has received a total of 36 recommendations
from professional institutions and clinical guidelines, and is primarily used for the treatment of
ischemic stroke and related diseases, making it one of the core therapeutic agents for the clinical
diagnosis and treatment of this indication. NBP has currently launched four “14th Five-Year”
research projects. Among these, the BLESS study on mild stroke and the IMPACT study on
cerebral small vessel disease, both initiated in 2025, are designed to generate high-level clinical
evidence for NBP’s sequential treatment regimen and long-term medication strategies spanning
six months to one year, thereby further solidifying its clinical position in stroke management.
– 11 –
•
Mingfule (明復樂®)
Mingfule is a third-generation specific thrombolytic drug independently developed with complete
independent intellectual property rights. As the first tenecteplase approved in China for the
indication of acute ischemic stroke (AIS), it has been included in multiple clinical treatment
guidelines. In 2025, the BRIDGE-TNK study (bridging therapy) and ANGEL-TNK study (nonbridging therapy) of Mingfule were respectively published in The New England Journal of
Medicine (NEJM) and The Journal of the American Medical Association (JAMA), providing
high-level evidence-based support for its use in endovascular treatment of acute stroke combined
with thrombolysis and in special patient populations. The TRACE-5 (Thrombolysis for Acute
Ischaemic Stroke with Posterior Circulation Occlusion Beyond the Time Window) study has been
accepted for publication in The Lancet, thereby further broadening the drug’s applicable scenarios.
In January 2026, the American Heart Association (AHA) and the American Stroke Association
(ASA) jointly released the 2026 Guidelines for the Early Management of Patients with Acute
Ischemic Stroke, formally elevating tenecteplase to a first-line intravenous thrombolytic agent on
par with alteplase. As a representative Chinese-developed tenecteplase, Mingfule has received
official recognition from internationally authoritative guideline. Moving forward, Mingfule will
continue to advance high-quality clinical research, deepen academic collaboration with leading
teams domestically and internationally, while accelerating market expansion. This will contribute
to improving China’s stroke care system and provide safer and more effective treatment options
for more patients.
In 2025, the sales revenue of NBP (恩必普®) experienced a decline due to the price deduction resulting
from the National Reimbursement Drug List (the “NRDL”) negotiations adjustments. However, this
price reduction significantly enhanced product accessibility, benefiting more patients and laying a
solid foundation for further market expansion. Impacted by the inclusion of its injection formulation
in the 10th Batch of the National Centralised Drug Procurement List, the sales revenue of Shuanling
(舒安靈®) experienced a substantial decline. Meanwhile, benefiting from the continuous accumulation
of high-quality evidence-based medical data and growing trust from clinicians and patients, Mingfule
(明復樂 ®) achieved substantial year-on-year growth. Oushuan (歐舒安 ®) and Oulaining (歐來寧 ®)
maintained a steady year-on-year growth trend.
Oncology
Major products include Duoenyi (多恩益®) (irinotecan hydrochloride liposome injection), Duoenda
(多恩達 ® ) (mitoxantrone hydrochloride liposome injection), Enshuxing (恩舒幸 ® ) (enlonstobart
injection), Keaili (克艾力®) (paclitaxel for injection (albumin-bound)), Jinyouli (津優力®) (PEG-rhGCSF injection), Geruite (戈瑞特®) (lenvatinib mesilate capsules) and Jinlitai (津立泰®) (narlumosbart
injection), etc.
– 12 –
•
Duoenyi (多恩益®)
Duoenyi is the first generic irinotecan hydrochloride liposome injection in China. It was approved
in September 2023 for use in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for
the treatment of patients with metastatic pancreatic cancer that have progressed after receiving
gemcitabine treatment. The 2024 CSCO Guidelines list the combination regimen as a Class I
recommendation for the treatment of metastatic pancreatic cancer in second-line and beyond and a
Class II recommendation for first-line treatment of pancreatic cancer. In December 2025, Duoenyi
secured approval for an additional indication, enabling its combination therapy with oxaliplatin,
5-FU and LV for the first-line treatment of metastatic pancreatic cancer. This milestone marks
it as the first irinotecan liposome injection within the country to gain authorisation for first-line
treatment of pancreatic cancer.
•
Duoenda (多恩達®)
Duoenda, a Class 2 new chemical drug developed by the Group, which was included in the
NRDL in 2023 for the treatment of relapsed/refractory peripheral T-cell lymphoma, is the world’s
first mitoxantrone liposomal formulation to obtain market approval and has secured patent
authorisations across multiple countries. At present, Duoenda is advancing clinical exploration for
multiple hematologic malignancy indications, including front-line treatment of peripheral T-cell
lymphoma (PTCL), diffuse large B-cell lymphoma, and acute myeloid leukemia. Concurrently, the
Company is accelerating its overseas market expansion to promote the international application of
this product.
•
Enshuxing (恩舒幸®)
Enshuxing is a Class 1 new therapeutic biological drug, for which the Group owns the invention
patent and complete independent property rights. The product obtained market approval in June
2024 and was included in the NRDL in the same year. Enshuxing is indicated for the treatment
of recurrent or metastatic cervical cancer with PD-L1 expression positive (CPS≥1) in patients
who have failed at least one line of platinum-containing chemotherapy. Clinical data have
demonstrated that Enshuxing, in combination with first-line therapy for patients with recurrent or
metastatic cervical cancer, achieved a median progression-free survival (mPFS) of 15.1 months,
showing significantly superior efficacy compared to similar products. In second-line and laterline monotherapy for patients with recurrent or metastatic cervical cancer, the median overall
survival (mOS) reached 21.3 months. Leveraging outstanding clinical data, this product has been
recommended by authoritative guidelines from five major societies/organisations, including
the National Health Commission, NCCN, Chinese Medical Association, CSCO, and CACA,
establishing it as one of the core treatment options for cervical cancer in China.
Since its launch, Enshuxing (恩舒幸®) has achieved rapid sales growth, with marketing efforts
primarily focused on gynecological tumors (including cervical cancer and endometrial cancer).
The Company is actively advancing its clinical research in solid tumors such as esophageal
cancer, colorectal cancer, and NSCLC, while accelerating overseas licensing collaborations.
– 13 –
•
Jinyouli (津優力®)
Jinyouli is the first long-acting white blood cell booster drug developed in China. It is a Class 1
new therapeutic biological drug used to prevent and treat incidence of infection and pyrexia due to
low neutrophil count in patients receiving chemotherapy. Through PEG modification technology,
the product significantly improves administration convenience and patient compliance, and has
been consistently recommended by authoritative guidelines domestically and internationally,
winning multiple national-level awards.
In 2025, sales revenue of this therapeutic area recorded a significant year-on-year decline, primarily
impacted by the inclusion of Duomeisu in the 10th Batch of the National Centralised Drug
Procurement List, resulting in substantial price reductions. At the same time, the expansion of the
centralised procurement policy in the Beijing-Tianjin-Hebei “3+N” Alliance led to a notable drop in
the sales revenue of Jinyouli. Encouragingly, the sales of new products launched in recent years, such
as Duoenyi and Enshuxing, have maintained steady growth, injecting new momentum into the business
of this therapeutic area.
Anti-infectives
Major products include Anfulike (安復利克 ® ) (amphotericin B cholesteryl sulfate complex for
injection), Ansulike (安速利克 ® ) (amphotericin B liposome for injection), Shuluoke (舒羅克 ® )
(meropenem for injection), Weihong (維宏 ® ) (azithromycin tablets/capsules/enteric tablets,
azithromycin for injection), Nuomoling (諾莫靈®) (amoxicillin capsules), Oujian (歐健®) (cefixime
capsules), Xianqu (先曲®) (ceftriaxone sodium for injection) and Xianwu (先伍®) (cefazolin sodium
for injection), etc.
•
Anfulike (安復利克®)
Anfulike was approved for marketing through priority review in March 2021 and included in the
NRDL in the same year for the treatment of patients with invasive fungal infections. This product
has undergone modifications of lipid structure, which significantly reduce the incidence of
nephrotoxicity and hypokalaemia, expand the applicable population, and help lower the medical
cost. Recognised for its clinical value and market demand, Anfulike is jointly recommended by
the Ministry of Industry and Information Technology and the National Health Commission of the
People’s Republic of China as a “clinically urgent, market-deficient” drug.
•
Ansulike (安速利克®)
Ansulike was approved for marketing in September 2024. As a polyene antibiotic, it is one of
the most potent and broad-spectrum drugs for the prevention and treatment of invasive fungal
diseases. Utilising a liposomal drug delivery system, it encapsulates amphotericin B in small
unilamellar liposomes (less than 100nm) composed of hydrogenated soybean phosphatidylcholine,
– 14 –
distearoyl phosphatidylglycerol, and cholesterol. Compared with other amphotericin B
injections available on the market, Ansulike mainly exists in liposomal form in the blood, which
significantly reduces the binding of free amphotericin B to renal tubular epithelial cells, thereby
markedly decreasing drug-induced nephrotoxicity and infusion-related adverse reactions, and
improving the therapeutic index and clinical tolerability.
In 2025, affected by weakened market demand, sales revenue of products such as Anfulike, Weihong,
and Xianqu declined; meanwhile, the newly launched Ansulike achieved rapid sales growth, becoming
a growth highlight; Shuluoke’s sales revenue rose steadily; and the revenue of Nuomoling and Oujian
remained relatively stable.
Cardiovascular
Major products include Xuanning (玄寧®) (maleate levamlodipine tablets/dispersible tablets), Encun
(恩存®) (clopidogrel bisulfate tablets), Yishuning (意舒寧®) (nifedipine controlled-release tablets),
Abikang (阿比康®) (aspirin enteric tablets), Mingfule (明復樂®) (recombinant human TNK tissue-type
plasminogen activator for injection (rhTNK-tPA)), Daxinning (達新寧®) (dronedarone hydrochloride
tablets) and Meiluolin (美洛林®) (ticagrelor tablets), etc.
•
Xuanning (玄寧®)
Xuanning is mainly used for the treatment of hypertension and angina (including chronic stable
angina and vasospastic angina), and is a product in the NRDL and National Essential Medicines
List (the “NEML”). The Group will continue to implement all-channel promotion strategy,
strengthen penetration into lower-tier markets and patient transition in and outside hospitals. At
the same time, the Group will enhance promotion in retail terminals and online platform, so as
to fully unleash the brand advantage of the product and increase the accessibility and medication
coverage.
•
Encun (恩存®)
Encun is a platelet aggregation inhibitor, which is mainly used to prevent atherosclerotic
thrombotic events such as myocardial infarction and ischemic stroke. As the first domestically
produced clopidogrel that has obtained the U.S. Food and Drug Administration (FDA) approval,
Encun adopts similar process and production lines to those in the U.S. market, achieving
simultaneous launch in China and the U.S.. It is also the preferred antithrombotic drug for acute
coronary syndrome (ACS) and preferred antiplatelet drug for stroke prevention recommended by
authoritative domestic and international guidelines and consensus. Leveraging stringent quality
control and international certification, Encun rapidly iterated domestically and its sales volume
ranked second only to the originator drug, and led other domestic competitors. Meanwhile, it
successfully entered overseas market such as the U.S., becoming as a model for the internalization
of domestic cardiovascular drugs. In the future, leveraging the international certification
and market advantage of Encun, the Company will deepen the cooperation with overseas
pharmaceutical companies as well as continue to consolidate and enhance its competitiveness in
domestic and global markets.
– 15 –
•
Mingfule (明復樂®)
Mingfule is a domestic innovative third-generation specific thrombolytic drug independently
developed by the Group based on the Chinese genome sequence, focusing on the thrombolysis
treatment in patients with acute myocardial infarction within 6 hours of onset. With its outstanding
efficacy and favorable safety, Mingfule is a preferred thrombolytic drug recommended by multiple
authoritative guidelines, including the Guidelines for the Rational Medication for Thrombolytic
Treatment of Acute ST-Segment Elevation Myocardial Infarction (2nd Edition), Chinese Expert
Consensus on Microcirculation Protection Strategies for Emergency PCI in Patients with STSegment Elevation Myocardial Infarction, and Expert Consensus on Intracoronary Thrombolysis
during Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial
Infarction (2025). Considering its clinical advantages in cardiovascular emergency care, Mingfule
has become an important treatment option in this area.
In 2025, affected by successful bidding in the centralised volume-based procurement program and its
subsequent price linkage, the revenue of Abikang and Encun experienced a decline. At the same time,
driven by market demand, Daxinning and Yishuning achieved revenue growth, while the revenue of
Xuanning remained stable.
Respiratory System
Major products include Yiluoda (伊絡達®) (nintedanib capsules), Enyitan (恩益坦®) (omalizumab for
injection), Qixin (琦昕®) (oseltamivir phosphate capsules), Nuoyian (諾一安®) (montelukast sodium
tablets/chewable tablets), Qixiao (琦效®) (arbidol hydrochloride tablets) and Zhongnuo Like (中諾立
克®) (ambroxol hydrochloride oral solution), etc.
•
Yiluoda (伊絡達®)
Yiluoda is the first generic nintedanib preparation in China, indicated for the treatment of
systemic sclerosis-associated interstitial lung disease (SSc-ILD), progressive fibrosing interstitial
lung diseases (PF-ILD) and idiopathic pulmonary fibrosis (IPF). Currently, all three of the
aforementioned indications have been included in the NRDL, providing strong support for the
robust growth of the product.
•
Enyitan (恩益坦®)
Enyitan is the first biosimilar drug of Xolair ® developed as Class 3.3 therapeutic biological
product in China. It is indicated for adults and adolescents (12 years of age and older) with
chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. In
February 2025, Enyitan received approval for the new indication of moderate to severe persistent
allergic asthma. The Global Strategy for Asthma Management and Prevention (GINA 2024) report
states that for patients 6 years of age and older with severe allergic asthma, IgE therapy (such as
omalizumab) is strongly recommended. The clinical equivalence of Enyitan with the original drug
has been verified through rigorous head-to-head clinical studies. Following its market launch,
it was rapidly incorporated into the recommended treatment pathways of the China Guidelines
– 16 –
for the Diagnosis and Treatment of Allergic Asthma (2025 Edition) and the Guidelines for the
Diagnosis and Treatment of Chronic Spontaneous Urticaria, and was included in the NRDL in
2025, significantly improving drug accessibility for patients with severe allergic diseases.
In 2025, Enyitan received marketing approval for the indication of allergic asthma, further enriching
the Group’s product portfolio in respiratory system therapeutic area and providing a new business
growth driver in this field. Meanwhile, the sales revenue of products such as Zhongnuo Like, Nuoyian
and Qixiao experienced varying degrees of decline due to market factors, the revenue of Qixin
achieved year-on-year growth, and the revenue of Yiluoda remained relatively flat year-on-year.
Digestion and Metabolism
Major products include Oubeituo (歐倍妥®) (esomeprazole capsules), Debixin (得必欣®) (omeprazole
capsules/tablets/injection), Shuanglexin (雙樂欣®) (metformin hydrochloride tablets/extended-release
tablets), Xinweiping (欣維平®) (acarbose tablets) and Linmeixin (林美欣®) (glimepiride dispersible
tablets), etc.
•
Oubeituo (歐倍妥®)
Oubeituo is the S-isomer of omeprazole, a core proton pump inhibitor with a more potent acidsuppressing effect and higher bioavailability. This product is consistently recommended by
authoritative domestic and international guidelines as the drug of choice for the treatment of
gastro-esophageal reflux disease and peptic ulcers. It can also be used in combination with
antibiotics for Helicobacter pylori (Hp) eradication therapy. Having passed consistency evaluation
and obtained the U.S. FDA certification, Oubeituo delivers originator-level quality while
significantly reducing patient burden. It stands as a preferred medication for its potent efficacy,
rapid onset of action, and suitability for both initial and long-term maintenance therapy.
•
Debixin (得必欣®)
Debixin, a classic proton pump inhibitor (PPI), is included in the NEML and classified as
Category A under the medical insurance. Recommended by numerous domestic and international
authoritative guidelines, it is indicated for the treatment of various gastric diseases caused by
excessive gastric acid.
In 2025, Xinweiping achieved steady revenue growth. However, due to intense market competition,
the unit price of Debixin declined following adjustments in sales strategy, which in turn dragged down
the overall sales revenue in this segment.
Other Therapeutic Areas
Major products include Celecoxib Capsules, Qimaite (奇邁特®) (tramadol hydrochloride tablets), Ove
(歐維®) (mecobalamin tablets), Roxadustat Capsules, Gubang (固邦®) (alendronate sodium tablets/
enteric tablets) and Lidocaine Hydrochloride Injection, etc.
– 17 –
Bulk Product Business
In 2025, the bulk product business recorded sales of RMB3,657 million, representing a year-on-year
increase of 2.1%.
Vitamin C
Sales revenue of Vitamin C products in 2025 amounted to RMB2,231 million, representing a yearon-year increase of 11.9%, primarily driven by rising demand in overseas markets, which led to an
uplift in sales revenue. The Group will focus on product quality, customer service, and sustainable
development while continuing to develop overseas sales networks to further increase its market share.
Antibiotics
Sales revenue of Antibiotics product in 2025 amounted to RMB1,426 million, representing a year-onyear decrease of 10.2%, primarily due to price reductions for penicillin and carbapenem products.
Functional Food and Other Businesses
In 2025, the functional food and other businesses recorded sales of RMB1,765 million, representing
a year-on-year increase of 4.5%, mainly due to steady growth in sales revenue of Guoweikang during
the year.
RESEARCH AND DEVELOPMENT
R&D expenses for the current period increased by 11.9% to RMB5,809 million as compared with
the same period last year, accounting for approximately 28.2% of the revenue from the finished drug
business. Currently, there are nearly 90 products in various stages of clinical trial, with 12 of them
having submitted application for marketing approval and nearly 30 key products in the registration
stage of clinical trials.
Regulatory Updates
From the beginning of 2025 to date, the regulatory progress of the Group in China is as follows:
5 new drugs have approved for marketing; 10 drugs have their marketing applications accepted; 5
Breakthrough Therapy Designations have been granted; 58 approvals for clinical trial have been
obtained; and 9 generic drugs granted registration approvals. In addition, the Group received clinical
trial approval for 18 innovative drugs and 1 Fast Track Designations in North America.
– 18 –
China
Marketing Approvals Obtained
Month
Drug Candidate
Indication
January 2025
Shanzeping (善澤平®) (prusogliptin tablets)
The improvement of glycemic control in adults with type 2 diabetes (including
monotherapy and combination therapy when metformin hydrochloride alone does not
provide adequate glycemic control)
February 2025
Enyitan (恩益坦®) (omalizumab for injection)
Treatment of moderate to severe persistent allergic asthma
June 2025
Meiluotai (美洛泰 ) (Meloxicam Injection (III))
Moderate to severe pain in adults
December 2025
Duoenyi (多恩益 )(irinotecan hydrochloride
liposome injection)
First-line treatment in combination with oxaliplatin, 5-fluorouracil (5-FU) and
leucovorin (LV) for patients with metastatic pancreatic cancer
January 2026
Clevidipine injectable emulsion
Treatment of patients with hypertension when oral therapy is not feasible or is
anticipated to be ineffective
®
®
Applications for Marketing Approval Accepted
Month
Drug Candidate
Indication
March 2025
Aprepitant injection
Prevention of postoperative nausea and vomiting
March 2025
Irinotecan liposome injection
First-line metastatic pancreatic cancer
March 2025
Paliperidone palmitate injection (1M)
Schizophrenia
June 2025
Pregabalin extended-release tablets
Diabetic peripheral neuropathic pain and postherpetic neuralgia
August 2025
Semaglutide injection
Glycemic control in adult patients with type 2 diabetes
September 2025
Anbentiamab injection (KN026)
For use in combination with chemotherapy for the treatment of patients with HER2positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction
cancer who have failed at least one prior systemic therapy (which must include
trastuzumab in combination with chemotherapy)
October 2025
Efmedaglutide alfa injection (TG103)
For long-term weight management in overweight or obese adults in combination with
diet control and increased physical activity
November 2025
Pertuzumab injection
HER2-positive breast cancer
December 2025
Semaglutide injection
Long-term weight management in overweight adults or obese patients, in conjunction
with diet control and increased physical activity
January 2026
Prusogliptin and metformin extended-release tablets
An adjunct to diet and exercise for adult patients with type 2 diabetes mellitus (T2DM)
who have inadequate glycemic control on metformin monotherapy or who are already
receiving combination therapy with prusogliptin and metformin
– 19 –
Breakthrough Therapy Designations (BTD) Granted
Month
Drug Candidate
Indication
January 2025
SYS6010
Monotherapy for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
after failure of EGFR-TKIs and platinum-based chemotherapy
February 2025
Sirolimus for Injection (albumin-bound)
Malignant perivascular epithelioid cell tumor (PEComa)
March 2025
Anbenitamab repodatecan (JSKN003)
All-comer population of patients with platinum-resistant recurrent epithelial ovarian
cancer, primary peritoneal carcinoma, or fallopian tube cancer
May 2025
JMT101
RAS, RAF, EGFR ECD and PIK3CA exon 20 wild-type advanced colorectal cancer after
failure of standard treatment in second-line or beyond
October 2025
Anbenitamab repodatecan (JSKN003)
Monotherapy for the treatment of patients with HER2-positive advanced colorectal
cancer who have previously failed treatment with oxaliplatin, fluorouracil, and irinotecan
Clinical Trial Approvals Obtained
First Indication
Month
Drug Candidate
Indication
January 2025
SYH2059 tablets (PDE4B inhibitor)
Interstitial lung disease
January 2025
SYS6045 for injection (ADC)
Advanced solid tumors
January 2025
SYS6041 for injection (FR α ADC)
Advanced solid tumors
February 2025
SYS6017 injection (VZV-mRNA vaccine)
Prevention of herpes zoster
March 2025
SYS6090 (Original: JMT108) injection (PD-1/IL15)
Advanced malignant tumors
March 2025
SYS6040 (DLL3 ADC)
Advanced solid tumors
March 2025
SYH2067 capsules (GLP-1 receptor agonists)
Weight management in overweight adults or obese patients, based on reduced-calorie
diet and increased physical activity
April 2025
SYH2046 tablets (ENPP1 inhibitor)
Heart failure after acute myocardial infarction
April 2025
Prusogliptin and metformin extended-release tablets
Diabetes
April 2025
SYH2068 injection (siRNA)
Hyperlipoproteinemia (a)
May 2025
JMT106 injection
Advanced solid tumors
July 2025
High-concentration hydroxocobalamin
hydrochloride injection
Methylmalonic academia (MMA)
August 2025
Dupilumab injection
Moderate-to-severe atopic dermatitis in adults
August 2025
SYS6036 injection
Multiple cancer types such as melanoma, NSCLC, esophageal cancer, and head and neck
squamous cell carcinoma
September 2025
SYH2066 tablets (RSV F protein inhibitor)
Respiratory infections caused by respiratory syncytial virus (RSV)
September 2025
Lecanemab injection
Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease
dementia
September 2025
SYH2070 injection (ANGPTL3 siRNA)
Hypertriglyceridemia or mixed hyperlipidemia
– 20 –
Month
Drug Candidate
Indication
October 2025
SYH2061 injection (C5 siRNA)
IgA nephropathy and other complement-mediated diseases
November 2025
SYH2056 tablets
Depression
November 2025
JMT206 injection
Weight management for individuals with obesity or overweight and at least one weightrelated comorbidity
December 2025
Daratumumab injection
Treatment of adult patients with multiple myeloma
December 2025
SYH2085 tablets
Treatment of uncomplicated influenza A and B in adults and adolescents aged 12 years
and older
December 2025
SYH2072 tablets
Uncontrolled hypertension and primary aldosteronism
December 2025
Prusogliptin, dapagliflozin and metformin
extended-release tablets
Used as an adjunct to diet and exercise for adult patients with type 2 diabetes mellitus
who have inadequate glycemic control with metformin hydrochloride monotherapy
December 2025
SYH2069 injection
Weight management for individuals with obesity or overweight and at least one weightrelated comorbidity
December 2025
Nintedanib esilate powder for inhalation
Idiopathic pulmonary fibrosis
January 2026
SYS6055 injection
Relapsed/refractory aggressive B-cell lymphoma
February 2026
Ropivacaine long-acting injection
Treatment of post-operative analgesia for adults
February 2026
Bempedoic acid tablets
As an adjunct to diet, used in combination with other low-density lipoprotein cholesterol
(LDL-C) lowering therapies, or alone if such therapies are not available, to reduce
LDL-C levels in adults with primary hyperlipidemia, including heterozygous familial
hypercholesterolemia (HeFH)
March 2026
Emicizumab injection (SYS6053)
Treatment of patients with Hemophilia A
March 2026
Indacaterol Acetate and Mometasone Furoate
Powder for Inhalation
Used as a maintenance treatment of asthma in adults and adolescents 12 years and older
Additional Indication
Month
Drug Candidate
Indication
January 2025
Paclitaxel cationic liposome for injection
In combination with systemic therapy for the treatment of liver metastases of advanced
solid tumors
January 2025
SYHX1901 tablets
In combination with other drugs for the treatment of solid tumors and hematological
tumors
January 2025
SYHA1813 oral solution
In combination with enlonstobart injection (SG001) for consolidation after synchronous/
sequential radiotherapy in limited stage small cell lung cancer
In combination with sirolimus for injection (albumin-bound) for the treatment of
advanced renal cell carcinoma in second-line and beyond
February 2025
SYS6002 for injection
In combination with JMT101 and SG001 for the treatment of advanced head and neck
squamous cell carcinoma and other advanced solid tumors
March 2025
JMT101
In combination with mitoxantrone liposome versus investigator’s choice of
chemotherapy as the treatment of nasopharyngeal cancer in third-line and beyond
April 2025
Anbenitamab repodatecan (JSKN003)
First-line and perioperative combination treatment of HER2-positive gastric cancer
April 2025
Recombinant human TNK tissue-type
plasminogen activator for injection
Acute ischemic stroke of longer time window (within 4.5–24 hours of onset)
April 2025
JMT601 injection
Primary membranous nephropathy
– 21 –
Month
Drug Candidate
Indication
April 2025
CM326 injection
Adolescent asthma
April 2025
Sirolimus for injection (albumin-bound)
In combination with palbociclib and fluvestrant for the first-line treatment of HRpositive/HER2-negative advanced breast cancer
August 2025
Docetaxel for injection (albumin-bound)
In combination with trastuzumab for injection and pertuzumab injection for the first-line
treatment of patients with HER2-positive recurrent metastatic breast cancer
August 2025
Sirolimus for injection (albumin-bound)
In combination with octreotide long-acting injection for the first-line treatment of
metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
August 2025
SYS6026 injection
HPV 16/18 type related advanced solid tumors
September 2025
Anbenitamab injection (KN026)
In combination with chemotherapy containing fluorouracil and platinum drugs with
or without enlonstobart for the first-line treatment of locally advanced unresectable or
metastatic HER2-positive gastric cancer or gastroesophageal junction cancer
September 2025
Docetaxel for injection (albumin-bound)
In combination with oxaliplatin, 5-fluorouracil and calcium folinate for the treatment of
advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma
September 2025
Paclitaxel cationic liposome for injection
In combination with systemic treatment for the treatment of advanced hepatocellular
carcinoma
September 2025
ALMB-0166
Parkinson’s disease, acute ischemic stroke, acute spinal cord injury, and other
neurological disorders
October 2025
Anbenitamab repodatecan (JSKN003)
Monotherapy or in combination with docetaxel (albumin-bound) or in combination with
others for neoadjuvant therapy for breast cancer
October 2025
Sirolimus for injection (albumin-bound)
In combination with SYS6043, SYS6010, DP303c, or SYS6002 for the treatment of
advanced solid tumors
October 2025
SYS6010 for injection
Neoadjuvant therapy for resectable stage II-IIIB EGFR-sensitive mutated NSCLC in
combination with osimertinib
November 2025
SYS6043 for injection
In combination with PD-1 or PD-L1 monoclonal antibody, with or without
chemotherapy, for the treatment of advanced small cell lung cancer and other advanced
solid tumors
December 2025
Anbenitamab injection (KN026)
Adjuvant therapy for early stage or locally advanced HER2-positive breast cancer in
combination with docetaxel for injection (albumin-bound) and chemotherapy
December 2025
Enlonstobart injection
In combination with SYS6026 injection for the treatment of HPV 16/18 type related
advanced solid tumors
January 2026
SYS6090 injection
For the treatment of locally advanced (phase IIIB/IIIC), metastatic (phase IV) NSCLC
and extensive-phase SCLC that are not amenable to curative treatment (not suitable for
complete surgical resection with curative intent or chemoradiotherapy)
January 2026
SYS6010 for injection
In combination with enlonstobart injection for adult patients with phase II-III NSCLC
who have received neoadjuvant therapy and did not achieve major pathological response
(non-MPR) after surgery
February 2026
SYS6023 for injection
In combination with other drugs for the treatment of unresectable locally advanced or
metastatic breast cancer
– 22 –
Registration Approvals Obtained
Since the beginning of 2025, a total of 9 generic drugs have obtained drug registration approvals,
namely regorafenib tablets, ilaprazole enteric-coated tablets, oseltamivir phosphate for oral suspension,
peramivir injection (300mg/60ml bag), vonoprazan fumarate tablets (20mg and 10mg), cobamamide
capsules, mesalazine enteric-coated tablets, pentoxifylline extended-release tablets and tacrolimus
extended-release capsules.
North America
Clinical Trial Approvals Granted by the U.S. FDA
Month
Drug Candidate
Indication
January 2025
SYS6043(B7-H3 ADC)
Advanced/metastatic solid tumors
February 2025
SYH2059 tablets (PDE4B inhibitor)
Interstitial lung disease
March 2025
SYH2051 tablets (selective ATM inhibitor)
Advanced solid tumors
April 2025
JMT203(GFRAL)
Cancer cachexia
April 2025
JMT108(PD–1/IL15)
Advanced malignant tumors
April 2025
SYS6041(FR α ADC)
Advanced solid tumors
April 2025
JMT202(FGFR1c/βKlotho)
Hypertriglyceridemia (HTG)
May 2025
SYH2046 tablets
Heart failure after acute myocardial infarction
June 2025
SYS6040 (DLL3 ADC)
Advanced solid tumors
September 2025
SYH2070 injection (ANGPTL3 siRNA)
Hypertriglyceridemia or mixed hyperlipidemia
November 2025
SYH2061 injection
Treatment of IgA nephropathy and other complement-mediated diseases
December 2025
SYH2056 tablets
Depression
December 2025
SYH2069 injection
Weight management for individuals with obesity or overweight and at least one weightrelated comorbidity
December 2025
JMT206
Weight management for individuals with obesity or overweight and at least one weightrelated comorbidity
January 2026
SYH2072 tablets
Uncontrolled hypertension and resistant hypertension
February 2026
SYH2082(GLP-1/GIP)
Long-term weight management in overweight or obese adults in combination with diet
control and increased physical activity
February 2026
Paclitaxel albumin nanoparticles (fast-dissolving)
Treatment of metastatic breast cancer after failure of combination chemotherapy or
breast cancer relapse within 6 months of adjuvant chemotherapy
March 2026
Highly selective PDE4B inhibitor (SYH2059
powder for inhalation)
Tulmonary fibrosis (PF), encompassing idiopathic pulmonary fibrosis (IPF) and
progressive pulmonary fibrosis (PPF)
– 23 –
Fast Track Designation Granted by the U.S. FDA
Month
Drug Candidate
Indication
May 2025
CPO301 (EGFR-ADC, also known as SYS6010
in China)
Adult patients with advanced or metastatic non-squamous non-small cell lung cancer
(Nsq-NSCLC) without EGFR mutations or other actional genomic alterations (AGA),
with prior disease progression on platinumbased chemotherapy and an anti-PD-(L)1
antibody
Major Clinical Trial Progress
Initiation/Enrollment of Pivotal Clinical Trial
Anbenitamab repodatecan (JSKN003)
•
In January 2025, the first subject was enrolled in the phase III clinical trial conducted in China
comparing investigator’s choice of chemotherapy for the second-line and third-line treatment of
HER2 low expressing recurrent/metastatic breast cancer.
•
In February 2025, the first subject was enrolled in the phase III clinical trial conducted in China
comparing TDM1 for the treatment of HER2-positive advanced breast cancer in second-line and
beyond.
•
In February 2026, the first subject was enrolled in the phase III clinical trial conducted in China
evaluating Anbenitamab repodatecan for the treatment of third-line HER2-positive advanced
colorectal cancer.
Ammuxetine hydrochloride enteric-coated tablets
•
In February 2025, the first subject was enrolled in the phase III clinical trial initiated in China
comparing positive control therapy for the treatment of depression.
SYS6010 for injection
•
In April 2025, the first subject was enrolled in the phase III clinical trial conducted in China for
the second-line treatment of EGFR mutant NSCLC.
Sirolimus for injection (albumin-bound)
•
In May 2025, the first subject was enrolled in the phase III clinical trial conducted in China for
use in combination with fulvestrant for the treatment of HR-positive/HER2-negative breast cancer
in second-line and beyond.
•
In June 2025, the first subject was enrolled in the phase Ib/III clinical trial conducted in China
for use in combination with palbociclib and fluvestrant for the first-line treatment of HR-positive/
HER2-negative breast cancer.
– 24 –
•
In September 2025, the first subject was enrolled in the phase II/III clinical trial conducted in
China of Sirolimus for injection plus octreotide versus everolimus for the treatment of metastatic
gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Paclitaxel cationic liposome for injection
•
In June 2025, the first subject was enrolled in the phase Ib/III clinical trial conducted in China of
combination systemic therapy for first-line treatment of colorectal cancer liver metastases.
SYHA1813 oral solution
•
In June 2025, the first subject was enrolled in the phase II/III clinical trial conducted in China in
combination with SG001 (Enshuxing (恩舒幸®)) for consolidation after radiotherapy in small cell
lung cancer.
SYHX1901 tablets
•
In June 2025, the first subject was enrolled in the phase III clinical trial conducted in China for
the treatment of moderate-to-severe plaque psoriasis.
JMT101 (recombinant humanised anti-epidermal growth factor receptor monoclonal antibody
injection)
•
In June 2025, the first subject was enrolled in the Part 2 of Phase III clinical trial conducted in
China of JMT101 injection in combination with osimertinib for the treatment of first-line EGFR
classical mutated NSCLC.
•
In October 2025, the first subject was enrolled in the Phase III clinical trial conducted in China of
JMT101 injection in combination with irinotecan compared with regorafenib for the treatment of
wild-type colorectal cancer in third-line and beyond.
Prusogliptin tablets
•
In July 2025, the first subject was enrolled in the phase III clinical trial conducted in China in
combination with dapagliflozin and metformin for the treatment of type 2 diabetes.
Hydroxocobalamin hydrochloride injection
•
In October 2025, the first subject was enrolled in the Phase III clinical trial conducted in China of
hydroxocobalamin hydrochloride injection for the treatment of methylmalonic academia (MMA).
– 25 –
Recombinant human TNK tissue-type plasminogen activator for injection
•
In November 2025, the first subject was enrolled in the Phase III clinical trial conducted in China
of recombinant human TNK tissue-type plasminogen activator for injection for the treatment of
acute ischemic stroke (within 4.5–24 hours of onset).
SYS6002 for injection (anti-Nectin-4 monoclonal antibody-drug conjugate for injection)
•
In December 2025, the first subject was enrolled in the Phase III clinical trial conducted in China
of SYS6002 for injection for the treatment of cervical cancer in second-line and beyond.
Octreotide long-acting injection
•
In January 2026, the first subject was enrolled in the Phase III clinical trial conducted in China
of Octreotide long-acting injection for the treatment of adjuvant treatment after pancreatic
neuroendocrine tumor surgery.
CM326 injection
•
In January 2026, the first site was initiated in the Phase III clinical trial conducted in China of
CM326 injection for the treatment of moderate-to-severe asthma.
•
In February 2026, the first site was initiated in the phase III clinical trial conducted in China of
CM326 injection for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
Anbentiamab injection (KN026)
•
In February 2026, the first site was initiated in the phase III clinical trial conducted in China of
anbentiamab injection in combination with docetaxel (albumin-bound) and chemotherapy for the
neoadjuvant treatment of HER2-positive breast cancer.
SYH2053 injection
•
In February 2026, the first site was initiated in the phase III clinical trial conducted in China of
SYH2053 injection in combination with statins for the treatment of primary hypercholesterolemia
and mixed dyslipidemia.
•
In February 2026, the first site was initiated in the phase III clinical trial conducted in China of
SYH2053 injection for the treatment of primary hypercholesterolemia and mixed dyslipidemia.
– 26 –
Last Subject Enrollment/Database Lock or Statistical Analysis Results of Pivotal Clinical Trials
Anbentiamab injection (KN026)
•
In April 2025, the last subject was enrolled in the phase III clinical trial conducted in China of
anbentiamab injection in combination with docetaxel (albumin-bound) compared with trastuzumab
and pertuzumab in combination with docetaxel injection for the first-line treatment of HER2positive breast cancer.
•
In July 2025, the clinical study summary report was completed for the phase II/III clinical trial
conducted in China of anbentiamab injection in combination with paclitaxel or irinotecan for the
treatment of HER2-positive gastric cancer in second line and beyond (including gastroesophageal
junction adenocarcinoma).
•
In August 2025, the last subject was enrolled in the phase III clinical trial conducted in China of
anbentiamab injection in combination with docetaxel (albumin-bound) compared with trastuzumab
and pertuzumab in combination with docetaxel injection for the neoadjuvant treatment of HER2positive breast cancer.
Daunorubicin cytarabine liposome for injection
•
In April 2025, the database lock was completed for bioequivalence clinical trials conducted in
China for the treatment of AML in the elderly patients who have not been previously treated.
Semaglutide injection
•
In June 2025, the clinical study summary report was completed for the phase III clinical trial of
semaglutide injection conducted in China for the treatment of type 2 diabetes.
•
In November 2025, the clinical trial summary report was completed for the phase III clinical trial
of semaglutide injection conducted in China for the treatment of overweight or obesity in adults.
Pertuzumab injection
•
In August 2025, the clinical trial summary report was completed for the phase III clinical trial
conducted in China, which evaluated the trastuzumab in combination with docetaxel for the
treatment of early or locally advanced HER2-positive breast cancer.
SG001 (recombinant fully human anti-PD-1 monoclonal antibody for injection)
•
In August 2025, the last subject was enrolled in the phase III clinical trial conducted in China of
SG001 injection in combination with chemotherapy, with or without bevacizumab, for the firstline treatment of recurrent or metastatic cervical cancer.
– 27 –
Valsartan levoamlodipine maleate tablets
•
In August 2025, the last subject was enrolled in the phase III clinical trial conducted in China for
the treatment of primary mild and moderate hypertension that cannot be effectively controlled by
monotherapy.
JMT103 injection (recombinant fully human anti-RANKL monoclonal antibody for injection)
•
In August 2025, the last subject was enrolled in the phase III clinical trial conducted in China of
JMT103 injection for the treatment of giant-cell tumor of bone.
•
In November 2025, the last subject was enrolled in the phase III clinical study conducted in China
of JMT103 injection for the treatment of bone metastases from malignant solid tumors.
Anbenitamab repodatecan (JSKN003)
•
In September 2025, the last subject was enrolled in the phase III clinical trial conducted in China
comparing TDM1 for the treatment of HER2-positive advanced breast cancer in second-line and
beyond.
Mitoxantrone hydrochloride liposome injection
•
In September 2025, the clinical trial summary report was completed for the phase III clinical trial
conducted in China for the treatment of relapsed/refractory peripheral T-cell lymphoma in secondline and beyond.
DP303c injection (recombinant humanised anti-HER2 monoclonal antibody-MMAE conjugate for
injection)
•
In November 2025, the clinical trial summary report was completed for the phase III clinical study
conducted in China of DP303c injection for the treatment of second-line and above HER2-positive
advanced breast cancer.
Secukinumab injection
•
In January 2026, the clinical trial summary report was completed for the phase III clinical study
conducted in China of secukinumab injection for the treatment of moderate-to-severe plaque
psoriasis.
Dextromethorphan bupropion extended-release tablets
•
In February 2026, the database lock was completed for the phase III clinical trial conducted
in China of dextromethorphan bupropion extended-release tablets for the treatment of adult
depression.
– 28 –
TG103 injection (GLP-1 receptor agonists)
•
In February 2026, the database lock was completed for the phase III clinical study conducted in
China of TG103 injection for the treatment of type 2 diabetes.
•
In February 2026, the database lock was completed for the phase III clinical study conducted in
China in combination with TG103 injection and metformin for the treatment of type 2 diabetes.
SYS6010 for injection
•
In February 2026, the last subject was enrolled in the phase III clinical study conducted in China
of SYS6010 for injection comparing platinum-based chemotherapy for the treatment of secondline EGFR-mutated NSCLC.
Publication of Major Results
Product
Study Title
Journals/Meetings
HA121-28 tablets (small molecule
tyrosine kinase inhibitor)
Phase I clinical trial of HA121-28 for the treatment of
Signal Transduct Target Ther (IF40.8)
patients with advanced solid tumors and Phase II clinical
study of HA121-28 for the treatment of patients with RET
fusion-positive NSCLC
Duoenda (多恩達®) (mitoxantrone
liposome)
Phase Ib clinical trial of mitoxantrone liposomal drug for the Oral Oncology (IF4.0)
treatment of head and neck squamous cell carcinoma
Peripheral T-cell lymphoma (PTCL) — Phase III trial
American Society of Hematology (ASH) Annual Meeting —
oral presentation
SWY321 (EGFR/c-METADC)
Non-clinical study
2025 American Association for Cancer Research (AACR)
Annual Meeting — poster presentation
SYH2039 (MAT2A small molecule
inhibitor)
Non-clinical study
2025 American Association for Cancer Research (AACR)
Annual Meeting — oral presentation
SYS6041 (FRαADC)
Non-clinical study
2025 American Association for Cancer Research (AACR)
Annual Meeting — poster presentation
SYS6042 (TROP2ADC)
Non-clinical study
2025 American Association for Cancer Research (AACR)
Annual Meeting — poster presentation
SYS6051 (TF-ADC)
Non-clinical study
2025 American Association for Cancer Research (AACR)
Annual Meeting — poster presentation
JMT206
Non-clinical study
2025 American ObesityWeek — oral presentation
SYH2082
Non-clinical study
2025 American ObesityWeek — poster presentation
CSPC-ALK7
Non-clinical study
2025 American ObesityWeek — poster presentation
JMT601 (CD20/CD47 bispecific
fusion protein)
Phase I trial of JMT601 for the treatment of CD20-positive
B-cell non-Hodgkin’s lymphoma
2025 American Association for Cancer Research (AACR)
Annual Meeting — poster presentation
Omalizumab for injection
Phase III equivalence clinical study of omalizumab for
injection in combination with Xolair® for the treatment of
patients with chronic spontaneous urticaria
Chinese Medical Journal (IF7.1)
– 29 –
Product
Study Title
Journals/Meetings
DBPR108 tablets (Prusogliptin
Tablets)
PK/PD study of DBPR108 tablets in patients with type 2
diabetes
Clinical Pharmacokinetics (IF4.6)
JMT101 injection (recombinant
humanised anti-epidermal growth
factor receptor monoclonal
antibody for injection)
Phase II clinical trial of JMT101 in combination with
2025 American Society of Clinical Oncology (ASCO) Annual
irinotecan and SG001 versus regorafenib for the treatment
Meeting — oral presentation
of patients with ≥3L colorectal cancer
2025 Chinese Society of Clinical Oncology (CSCO) — poster
presentation
Sirolimus for injection (albuminbound)
JMT101+ Docetaxel (albumin-bound) — Phase II study of
lung cancer
European Society for Medical Oncology Asia (ESMO Asia) —
oral presentation
JMT101-003
2026 European Lung Cancer Congress (ELCC) — mini oral
presentation
Phase I clinical trial of Sirolimus for injection (albuminbound) for the treatment of PEComa
European Society for Medical Oncology (ESMO Sarcoma)
Congress — oral presentation
Breast cancer-Phase II trial
European Society for Medical Oncology (ESMO) Congress —
poster presentation
San Antonio Breast Cancer Symposium (SABCS) -poster
spotlight
ALMB–0166
Phase I/II clinical trial of ALMB–0166 in patients with acute American Academy of Neurology (AAN) Annual Meeting —
spinal cord injury
oral presentation and poster presentation
ALMB–0168
Phase I clinical trial of ALMB–0168 in patients with
osteosarcoma
2025 American Society of Clinical Oncology (ASCO) Annual
Meeting — oral presentation
Case report
Antibody Therapeutic (IF4.5) — acceptance
Phase I clinical trial of SYS6010 for the treatment of
advanced solid tumors
2025 American Association for Cancer Research (AACR)
Annual Meeting — oral presentation
Investigator initiated trial (IIT) of SYS6010 in combination
with SYH2051 for the treatment of patients with
gastrointestinal cancers symposium
2025 American Society of Clinical Oncology (ASCO)
Annual Meeting — poster presentation
Phase I clinical trial of SYS6010 for the treatment of
advanced solid tumors
2026 American Association for Cancer Research (AACR)
Annual Meeting — Plenary Session oral presentation
SYS6010 (humanised anti-human
EGFR monoclonal antibody-JS-1
conjugate injection)
Paclitaxel cationic liposome
Investigator initiated trial (IIT) of paclitaxel cationic
2025 American Society of Clinical Oncology (ASCO) Annual
liposome for the treatment of patients with advanced solid
Meeting — online presentation
tumors (arterial infusion chemotherapy)
Ustekinumab injection
Phase III equivalence clinical trial of ustekinumab injection Journal of American Academy of Dermatology (JAAD, IF12.8)
in combination with Stelara (喜達諾®) for the treatment of American Academy of Dermatology (AAD) Annual Meeting
moderate-to-severe plaque psoriasis
— poster presentation
Enlonstobart injection (SG001)
Phase III clinical trial of Enlonstobart injection (SG001)
in combination with chemotherapy for the treatment of
cervical cancer
Society of Gynecologic Oncology (SGO) — poster presentation
SG001 — Phase Ib trial for advanced solid tumor
Drug Design Development and Therapy (IF5.1) — acceptance
– 30 –
Product
Study Title
Journals/Meetings
arlumosbart injection (JMT103)
Phase Ib clinical trial of Narlumosbart injection (JMT103)
for the treatment of bone metastases
International journal of cancer (IF5.7)
Phase II trial for postmenopausal osteoporosis
eClinicalMedicine (IF9.6)
Real-world study on giant cell tumor of bone
Cancer Medicine (IF4.0) — accepted
Docetaxel for injection (albuminbound) (HB1801)
Phase II trial of Docetaxel for injection (HB1801) comparing American Society of Clinical Oncology Annual Meeting
to Taxotere for the treatment of gastric cancer
— Gastrointestinal Diseases Session (ASCO GI)
— oral presentation
Anbenitamab injection (KN026)
Anbenitamab injection in combination with Paclitaxel or
Irinotecan — Phase III Trial for ≥2L HER2-Positive
Gastric Cancer
European Society for Medical Oncology Congress (ESMO) —
Late Breaking Abstract — proffered oral presentation
Anbenitamab injection — Phase II trial for Gastric Cancer
Cancer Comminications (IF24.9)
Anbenitamab injection — Phase III trial for Gastric Cancer
Annals of Oncology (IF65.4) — accepted
Phase I trial for advanced solid tumor
European Society For Medical Oncology Congress (ESMO) —
poster presentation
Phase II trial of Simmitinib in combination with Irinotecan
liposome for the treatment of advanced esophageal
squamous carcinoma
European Society For Medical Oncology Congress (ESMO) —
poster presentation
JMT203
Phase I trial for Cachexia
European Society For Medical Oncology Congress (ESMO) —
poster presentation
Ammuxetine
Phase II trial for Depression
Journal JAMA Network Open (IF10.5)
SYHA1813 oral solution
Phase I trial for Glioma
Annals of Clinical and Translational Neurology (IF5.1)
SYHX1901
Phase II trial for Plaque Psoriasis
J Am Acad Dermatol (IF12.8)
SYHX2011 (Albumin-Bound
Paclitaxel II)
Phase III trial for Advanced Breast Cancer
San Antonio Breast Cancer Symposium (SABCS) — poster
presentation
DP303c
Phase III trial for Advanced Breast Cancer versus T-DM1
San Antonio Breast Cancer Symposium (SABCS) — Late
breaking — Rapid Fire Presentation
Irinotecan Liposome Injection
Irinotecan Liposome — Phase II trial for IL Pancreatic
Cancer
Nature Communications (IF14.7) — accepted
SYS6043
SYS6043 — Phase I trial for Advanced Solid Tumors
2026 Society of Gynecologic Oncology (SGO) Annual Meeting
on Women’s Cancer — Scientific Plenary oral presentation
Simmitinib hydrochloride tablets
2026 10th International Conference on Innovative Approaches
in Head and Neck Oncology (ICHNO) — oral presentation
(LBA Proffered Paper)
– 31 –
Clinical Pipeline Overview
Registration and Pivotal Trial of Key Products
Applications for Marketing Approval Submitted in China
Drug candidate
Type
Target
Indication
Batoclimab
Biological drug
(monoclonal antibody)
Biological drug
(monoclonal antibody)
Nanodrug
FcRn
Myasthenia gravis
IL-12/IL-23p40
Psoriasis
Microtubule inhibitor
Breast cancer
Chemical drug
NK1 receptor antagonist
Paliperidone palmitate
injection (1M)
Pregabalin extended-release
tablets
Semaglutide injection
Chemical drug
Prevention of postoperative nausea and
vomiting
Schizophrenia
Anbenitamab injection
(KN026)
Biological drug
Efmedaglutide Alfa injection
(TG103)
Biological drug
Pertuzumab injection
Semaglutide injection
Biological drug
Chemical drug
Prusogliptin and Metformin
extended-release tablets
Chemical drug
D2 and 5-HT2A receptor
antagonist
GABA receptor modulator Diabetic peripheral neuropathic painand
post-herpetic neuralgia
GLP–1 receptor agonist
Glycemic control in adults with type 2
diabetes mellitus
HER2 bispecific antibody For use in combination with chemotherapy
for the treatment of patients with HER2positive locally advanced, recurrent, or
metastatic gastric or gastroesophageal
junction cancer who have failed at least
one prior systemic therapy (which must
include trastuzumab in combination with
chemotherapy)
GLP–1 receptor agonist
For long-term weight management in adults
AGONIST
in combination with diet control and
increased physical activity
HER2 monoclonal antibody HER2-positive breast cancer
GLP–1 receptor agonist
The long-term weight management
in overweight or obese adults in
combination with diet control and
increased physical activity
DPP4i/MET
Type 2 diabetes mellitus
Ustekinumab injection
Paclitaxel for injection
(albumin-bound) II
(SYHX2011)
Aprepitant injection
Chemical drug
Chemical drug
– 32 –
Applications for Marketing Approval Submitted in the U.S.
Drug candidate
Type
Target
Indication
Amphotericin B liposome
for injection
Irinotecan hydrochloride
liposome injection
Nanodrug
Invasive fungal infection
Nanodrug
Anti-infective,
nonspecific drug
Topoisomerase inhibitor
Type
Target
Indication(s)
DP303c injection
Biological drug
(recombinant humanised
anti-HER2 monoclonal
antibody-MMAE
conjugate for injection)
JMT101 injection
Biological drug
(recombinant humanised
(monoclonal antibody)
anti-epidermal growth
factor receptor monoclonal
antibody injection)
Anbenitamab injection
Biological drug
(KN026)
(bispecific antibody)
HER2 receptor (ADC)
Breast cancer
EGFR
EGFR exon 20 insertion NSCLC/EGFR
mutant NSCLC/colorectal cancer
HER2 bispecific antibody
Efmedaglutide alfa injection
(TG103)
Daunorubicin cytarabine
liposome for injection
Docetaxel for injection
(albumin-bound)
Mitoxantrone hydrochloride
liposome injection
Recombinant fully human
anti-RANKL monoclonal
antibody for injection
(JMT103; Narlumosbart
injection)
GLP-1 receptor agonist
First-line HER2‑positive gastric cancer/
First-line HER2‑positive recurrent or
metastatic breast cancer/Neoadjuvant
therapy for HER2‑positive breast cancer/
Adjuvant therapy for HER2‑positive
breast cancer
Diabetes
RNA/DNA polymerase
inhibitor
Microtubule inhibitor
Adult previously untreated high-risk
(secondary) AML
Gastric cancer/Pancreatic cancer
Cell-cycle non-specific
drug
RANKL
Nasopharyngeal cancer
Pancreatic cancer
Pivotal Trials in China
Drug candidate
Biological drug
(monoclonal antibody)
Nanodrug
Nanodrug
Nanodrug
Biological drug
(monoclonal antibody)
– 33 –
Bone metastasis of malignant solid tumors/
Giant-cell tumor of bone
Drug candidate
Type
Target
Indication(s)
Pilocarpine hydrochloride
eye drops
Secukinumab injection
Chemical drug
Presbyopia
Sirolimus for injection
(albumin-bound)
Nanodrug
Cholinergic muscarinic
agonist
IL-17 monoclonal
antibody
JAK&SYK dual-target
inhibitor
mTOR inhibitor
Irinotecan hydrochloride
liposome injection
Simmitinib hydrochloride
tablets
Nanodrug
Topoisomerase inhibitor
Chemical drug
SYS6010 for injection
Biological drug
FGFR1-3&KDR&CSF1R
multi-targeted small
molecule kinase
inhibitor
EGFR (ADC)
Valsartan levoamlodipine
maleate tablets
Ammuxetine hydrochloride
enteric-coated tablets
Chemical drug
Dextromethorphan bupropion
extended-release tablets
Anbenitamab repodatecan
(JSKN003)
Chemical drug
SYHA1813 oral solution
Chemical drug
Prusogliptin tablets
Chemical drug
SYHX1901 tablets
Biological drug
(monoclonal antibody)
Chemical drug
Chemical drug
Biological drug
Psoriasis
Moderate-to-severe plaque psoriasis
Perivascular epithelioid cell tumor
(PEComa)/First-line and second-line
treatment of breast cancer/metastatic
gastroenteropancreatic neuroendocrine
tumors (GEP-NETs)
Adjuvant therapy for pancreatic cancer
Esophageal squamous cell carcinoma
Treatment-naive and TKI-resistant EGFR
mutant NSCLC/esophageal squamous
cell carcinoma
Hypertension
Angiotensin II receptor
blocker
5-Hydroxytryptamine and Depression
norepinephrine reuptake
inhibitors
NMDA receptor
Depression
antagonist
HER2 bispecific anti-ADC Treatment of patients with HER2- positive
breast cancer in second-line and beyond/
HER2 low expressing breast cancer/
platinum resistant recurrent epithelial
ovarian cancer, primary peritoneal
carcinoma, or fallopian tube cancer
in second-line and beyond/Third-line
HER2-positive advanced colorectal
cancer
VEGFR/CSF1R
Consolidation therapy after
chemoradiotherapy for small cell lung
cancer
DPP4 inhibitor
Diabetes (combination treatment)
– 34 –
Drug candidate
Type
Target
Indication(s)
Recombinant fully human
anti-PD-1 monoclonal
antibody (SG001;
Enshuxing (恩舒幸®))
Recombinant human TNK
tissue-type plasminogen
activator for injection
(Mingfule (明復樂®))
Paclitaxel cationic liposome
for injection
Biological drug
PD–1
First-line treatment of recurrent or
metastatic cervical cancer
Biological drug
Recombinant human
Ischemic stroke
tissue-type plasminogen
(within 4.5-24 hours of onset)
activator
Chemical drug
Colorectal liver metastasis
High-concentration
hydroxocobalamin
hydrochloride injection
SYS6002 for injection
(Anti-Nectin-4 monoclonal
antibody — drug conjugate
for injection)
CM326 recombinant
humanised monoclonal
antibody injection
Octreotide Long-Acting
Injection
SYH2053 Injection
Chemical drug
Microtubule
depolymerization
inhibitor
cbl (VitB12)
Biological drug
Nectin-4 ADC
End-line cervical cancer
Biological drug
Anti-TSLP monoclonal
antibody
Moderate to severe asthma/chronic sinusitis
with nasal polyps
Chemical drug
Artificially synthesized
somatostatin
PCSK9 inhibitor (siRNA)
Postoperative adjuvant therapy for
pancreatic neuroendocrine tumors
Primary hypercholesterolemia and mixed
dyslipidemia
Chemical drug
Methylmalonic academia (MMA)
Awards and Patents
In March 2025, the Group’s project on “Key Technology and Industrial Application of Novel
Excipients for High-end Preparations” was awarded the Second Prize of Scientific and Technological
Innovation Achievements of the China Industry-University-Research Institute Collaboration
Association.
In July 2025, the Group’s project on “Key Technology Research and Industrialisation of Dronedarone
Hydrochloride” was awarded the Second Prize of Science and Technology Award of the China
Pharmaceutical Association.
In December 2025, the Group’s project on “Key Technology Development and High Value
Application of 1,3,7-Trimethylxanthine” was awarded the Third Prize of the Hebei Provincial Science
and Technology Progress Award.
– 35 –
From January 2025 to February 2026, 60 international patent applications under the Patent Cooperation
Treaty (the “PCT”) and 581 patent applications (290 domestic and 291 overseas) were filed by the
Group, and 87 patents (33 domestic and 54 overseas) were granted to the Group.
As at 28 February 2026, cumulatively 268 international patent applications under the PCT and 2,666
patent applications (1,645 domestic and 1,021 overseas) were filed by the Group, and 1,065 patents (677
domestic and 388 overseas) were granted to the Group.
Business Development
The Group has continuously strengthened its internal innovation capabilities, with R&D investment
increasing year by year. At present, we have built a robust R&D pipeline and accumulated numerous
high-quality innovative assets. In recent years, through out-licensing innovative products and forming
strategic collaborations with multinational pharmaceutical companies, we have actively advanced
the internationalisation of our R&D pipeline and accelerated the transformation of our innovation
achievements into global market.
Out-Licensing
SYS6005 (ADC)
In February 2025, the Group entered into an exclusive license agreement with Radiance Biopharma,
Inc. to out-license the development and commercialisation rights of SYS6005 in the U.S., the European
Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North
Macedonia, Serbia, Australia, and Canada. The Group will receive upfront payments of US$15 million
and is also entitled to receive potential development milestone payments of up to US$150 million and
potential sales milestone payments of up to US$1,075 million, plus tiered royalties.
Irinotecan Liposome Injection
In May 2025, the Group entered into an exclusive license agreement with Cipla USA, Inc. to outlicense the commercialisation right of irinotecan liposome injection in the U.S. The Group will receive
upfront payments of US$15 million and is also entitled to receive potential first commercial sales
and regulatory milestone payments of up to US$25 million and potential additional commercial sales
milestone payments of up to US$1,025 million, plus tiered royalties.
– 36 –
Strategic Research Collaboration on AI-driven Drug Discovery Platform
In June 2025, the Group entered into a strategic research collaboration agreement with AstraZeneca
for the discovery and development of novel oral small molecule candidates utilising the Group’s AIdriven, dual-engine efficient drug discovery platform. The Group agreed to discover pre-clinical
candidates (“PCC”) for multiple targets as selected by AstraZeneca with potential to treat diseases
across indications, including a pre-clinical small molecule oral therapy for immunological diseases.
For each PCC program, AstraZeneca shall have rights to exercise the option for an exclusive license
for development, manufacturing and commercialisation worldwide. The Group will receive an upfront
payment of US$110 million, and is also entitled to receive up to US$1,620 million in potential
development milestone payments and up to US$3,600 million in potential sales milestone payments,
plus tiered royalties.
SYH2086
In July 2025, the Group entered into an exclusive license agreement with Madrigal Pharmaceuticals,
Inc. to out-license the exclusive rights to develop, manufacture and commercialise SYH2086
worldwide, while retaining the Group’s right to develop and commercialise other orally administered
small-molecule GLP-1 receptor agonist products in China. The Group is entitled to receive a total
consideration of up to US$2,075 million, including an upfront payment of US$120 million plus
potential development, regulatory and commercial milestone payments of up to US$1,955 million, and
up to double-digit royalties.
Sustained-Release Drug Delivery Technology Platform and AI-driven Peptide Drug Discovery
Platform
In January 2026, the Group entered into a strategic collaboration and license agreement with
AstraZeneca for the development of innovative long-acting peptide medicines, utilising the Group’s
sustained-release delivery technology platform and AI-driven peptide drug discovery platform. The
Group will grant AstraZeneca exclusive worldwide rights (excluding the Chinese Mainland, the Hong
Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan) to its
portfolio of once-monthly injectable weight management products, comprising one clinical-ready asset,
SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I, three preclinical programmes
with differing mechanisms, and four additional new programmes. For access to eight programmes, as
well as these platforms, by AstraZeneca, the Group will receive an upfront payment of US$1.2 billion
and is also eligible to receive up to US$3.5 billion in potential research and development milestone
payments and up to US$13.8 billion in potential sales milestone payments, plus tiered royalties.
– 37 –
FINANCIAL REVIEW
Financial Results
Revenue and Gross Profit Margin
Revenue for the year amounted to RMB26,006 million, a decrease of 10.4% compared to RMB29,009
million in 2024. The decrease was mainly due to the inclusion of two products, Duomeisu and
Jinyouli, in centralised procurement. Gross profit margin slightly decreased by 4.4 percentage point to
65.6%.
Other Income
Other income for the year amounted to RMB755 million (2024: RMB561 million), mainly consisting
of interest income on bank deposits and balances of RMB196 million (2024: RMB232 million),
government grant income of RMB210 million (2024: RMB129 million) and agency income of RMB73
million (2024: RMB118 million).
Other gains or losses, net
A net gain of RMB258 million was recorded for the year (2024: net loss of RMB118 million), mainly
consisting of fair value gain on financial assets measured at FVTPL of RMB296 million (2024: loss of
RMB152 million) , net foreign exchange loss of RMB34 million (2024: net gain of RMB20 million)
and fair value gain on structured bank deposits of RMB39 million (2024: gain of RMB47 million).
Operating Expenses
Selling and distribution expenses for the year amounted to RMB6,463 million, a decrease of 25.4%
compared to RMB8,662 million in 2024. During the year, the Group continued to expand the market
coverage of each product and actively promote the newly launched products, but the selling expenses
of products winning bids in centralised procurement decreased significantly.
Administrative expenses for the year amounted to RMB825 million, a decrease of 23.5% compared
to RMB1,080 million in 2024. The decrease was mainly due to the Group’s strengthened control over
expenses and optimization.
R&D expenses for the year amounted to RMB5,809 million, an increase of 11.9% compared to
RMB5,191 million in 2024. The increase was primarily attributable to the steady increase in spending
on ongoing and newly initiated clinical trials.
– 38 –
Income tax expense
Income tax expenses for the year amounted to RMB932 million (2024: RMB1,240 million), which
represented provision of income tax expense based on the taxable income of each subsidiary and PRC
withholding tax on dividend distributions by certain subsidiaries. The effective tax rate, being the ratio
of tax expenses to profit before tax for the year, was 19.4% (2024: 22.2%).
Non-HKFRS Accounting Standards Measure
For the purpose of assessing the performance of the Group, the Company has also presented the
underlying profit attributable to shareholders of the Company as an additional financial measure
that is not required by, or presented in accordance with HKFRS Accounting Standards. The
Group believes that this non-HKFRS Accounting Standards measure better reflects its underlying
operational performance by eliminating certain non-operating items that are considered indicative of
its operational performance. However, the presentation of this non-HKFRS Accounting Standards
measure is not intended to be a substitute for, or superior to, the financial information prepared and
presented in accordance with HKFRS Accounting Standards.
Additional information is provided below to reconcile reported and underlying profit attributable to
shareholders of the Company:
2025
(RMB’000)
2024
(RMB’000)
Reported profit attributable to shareholders of the Company
Adjustment for:
— Fair value (gain)/loss on financial assets measured
at FVTPL (note a)
— (Reversal of) employee share-based compensation
expense (note b)
— Effect of corresponding income tax
3,882,108
4,328,035
(296,263)
151,936
(65,948)
14,429
210,454
(7,516)
Underlying profit attributable to shareholders of the Company
3,534,326
4,682,909
Notes:
(a)
Fair value (gain)/loss on financial assets measured at FVTPL arises from the measurement of the Group’s
investments in certain partnerships, funds and listed equity securities at fair value.
(b) Of the total employee share-based compensation expenses reversed during the year, the Company reversed an
expense of RMB77,292,000 (2024: recognised an expense of RMB198,319,000) in respect of share awards
granted to selected employees of the Group by Key Honesty Limited, a shareholder of the Company.
– 39 –
Liquidity and Financial Position
In 2025, the Group’s operating activities generated a net cash inflow of RMB5,832 million (2024:
RMB4,535 million). Turnover days of trade receivables (ratio of balance of trade receivables to sales,
inclusive of value added tax for sales in China) was 65 days, higher than 62 days in 2024. The Group
will strengthen its control and management in this aspect. Turnover days of inventories (ratio of
balance of inventories to cost of sales) was 126 days, lower than 132 days in 2024. Current ratio was 2.2
as at 31 December 2025, lower than the ratio of 2.3 in 2024. Capital expenditure for the year amounted
to RMB1,900 million (2024: RMB2,104 million), which was mainly used to construct production
facilities and improve production efficiency.
The Group’s financial position remained solid. As at 31 December 2025, the Group had bank deposits,
balances and cash of RMB9,481 million (2024: RMB9,187 million), structured bank deposits of
RMB2,776 million (2024: RMB1,307 million) and bank borrowings of RMB329 million (2024:
RMB392 million). As at 31 December 2025, gearing ratio (ratio of bank borrowings to total equity)
was 1.0% (2024: 1.2%).
The Group’s sales are primarily denominated in Renminbi for domestic sales in China and US dollars
for export sales. The Group effectively manages its foreign exchange risks by closely monitoring its
foreign exchange exposures and mitigating the impact of foreign currency fluctuations through the use
of appropriate hedging arrangements when considered necessary.
Pledge of Assets
As at 31 December 2025, the Group did not have any bank deposits (2024: RMB44 million) pledged to
secure short-term banking facilities.
Contingent Liabilities
The Group did not have any material contingent liabilities as at 31 December 2025.
Employees
The Group employed a total of approximately 19,700 employees as at 31 December 2025, with a
majority of them employed in the Chinese Mainland. The Group continues to offer competitive
remuneration packages, discretionary share options, share awards and bonuses to eligible staff, based
on the overall performance of the Group and the individual employees.
– 40 –
CONSOLIDATION FINANCIAL STATEMENTS
CONSOLIDATED INCOME STATEMENT
For the year ended 31 December 2025
Notes
Revenue
Cost of sales
3
Gross profit
Other income
Other gains or losses, net
Selling and distribution expenses
Administrative expenses
Research and development expenses
Other expenses
Share of results of associates
Share of results of joint ventures
Finance costs
2025
RMB’000
2024
RMB’000
26,005,980
(8,947,477)
29,009,254
(8,710,543)
17,058,503
754,949
258,450
(6,463,271)
(825,460)
(5,808,743)
(75,271)
(42,495)
(9,950)
(38,595)
20,298,711
561,089
(118,149)
(8,662,306)
(1,079,603)
(5,190,656)
(97,213)
(45,922)
(43,552)
(43,673)
Profit before tax
Income tax expense
5
4,808,117
(931,727)
5,578,726
(1,239,901)
Profit for the year
4
3,876,390
4,338,825
3,882,108
(5,718)
4,328,035
10,790
3,876,390
4,338,825
RMB cents
RMB cents
33.98
33.98
36.87
36.87
Profit for the year attributable to:
Owners of the Company
Non-controlling interests
Earnings per share
— Basic
— Diluted
6
– 41 –
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended 31 December 2025
2025
RMB’000
2024
RMB’000
3,876,390
4,338,825
(150,082)
(12,453)
26,338
(29,594)
Other comprehensive expense for the year, net of income tax
(123,744)
(42,047)
Total comprehensive income for the year
3,752,646
4,296,778
Total comprehensive income for the year attributable to:
Owners of the Company
Non-controlling interests
3,758,364
(5,718)
4,285,988
10,790
3,752,646
4,296,778
Profit for the year
Other comprehensive expense:
Item that will not be reclassified to profit or loss:
Fair value loss on financial assets measured at
fair value through other comprehensive income,
net of income tax
Item that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations
– 42 –
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
At 31 December 2025
2025
RMB’000
2024
RMB’000
12,153,162
1,336,253
71,565
234,904
2,774,871
754,737
710,849
2,251,276
211,505
556,488
3,391,691
11,374,442
1,128,458
56,127
234,904
2,609,506
815,094
711,799
2,334,120
250,297
576,100
2,410,000
24,447,301
22,500,847
3,090,736
4,778,867
1,507,394
3,580,982
343,686
83,468
–
2,775,915
6,089,565
3,130,014
5,160,672
887,059
4,035,490
359,123
65,475
166,105
1,307,007
6,777,199
22,250,613
21,888,144
2,322,004
5,334,111
662,247
653,624
305,545
210,788
131,693
229,131
328,723
1,667,247
5,741,793
283,901
945,753
272,659
133,965
58,991
137,514
392,204
10,177,866
9,634,027
Net current assets
12,072,747
12,254,117
Total assets less current liabilities
36,520,048
34,754,964
Notes
Non-current assets
Property, plant and equipment
Right-of-use assets
Investment property
Goodwill
Intangible assets
Interests in associates
Interests in joint ventures
Other financial assets
Deferred tax assets
Deposits, prepayments and other receivables
Bank deposits
9
Current assets
Inventories
Trade receivables
Deposits, prepayments and other receivables
Bills receivables
Amounts due from related companies
Amounts due from joint ventures
Other financial assets
Structured bank deposits
Bank deposits, balances and cash
8
9
10
Current liabilities
Trade payables
Other payables
Contract liabilities
Bills payables
Amounts due to related companies
Amounts due to joint ventures
Lease liabilities
Tax liabilities
Bank borrowings
11
12
13
– 43 –
2025
RMB’000
2024
RMB’000
563,241
851,136
180,693
374,861
407,808
–
56,135
424,731
1,969,931
888,674
Net assets
34,550,117
33,866,290
Capital and reserves
Share capital
Reserves
11,061,429
22,116,738
11,032,752
21,231,943
Equity attributable to owners of the Company
Non-controlling interests
33,178,167
1,371,950
32,264,695
1,601,595
Total equity
34,550,117
33,866,290
Notes
Non-current liabilities
Other payables
Contract liabilities
Lease liabilities
Deferred tax liabilities
12
– 44 –
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1.
BASIS OF PREPARATION
The consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards
(which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (“HKASs”)
and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”) and on
the historical cost basis except for certain financial instruments that are measured at fair value at the end of the
reporting period.
The financial information relating to the years ended 31 December 2025 and 2024 included in this preliminary
announcement of 2025 annual results does not constitute the Company’s statutory annual consolidated financial
statements for those years but is derived from those financial statements. Further information relating to these
statutory financial statements required to be disclosed in accordance with section 436 of the Hong Kong
Companies Ordinance is as follows:
•
The Company has delivered the financial statements for the year ended 31 December 2024 to the Registrar
of Companies as required by section 662(3) of, and Part 3 of Schedule 6 to, the Hong Kong Companies
Ordinance and will deliver the financial statements for the year ended 31 December 2025 in due course.
•
The Company’s auditor has reported on the financial statements of the Group for the years ended 31
December 2025 and 2024. The auditor’s reports for both years were unqualified; did not include a reference
to any matters to which the auditor drew attention by way of emphasis without qualifying its reports; and did
not contain a statement under sections 406(2), 407(2) or (3) of the Hong Kong Companies Ordinance.
The consolidated financial statements are presented in Renminbi (“RMB”), which is also the functional currency
of the Company.
2.
APPLICATION OF NEW AND AMENDMENTS TO HKFRS ACCOUNTING STANDARDS
Amendments to HKFRS Accounting Standards that are mandatorily effective for the current year
In the current year, the Group has applied the following amendments to a HKFRS Accounting Standard issued
by the HKICPA for the first time, which are mandatorily effective for the Group’s annual period beginning on 1
January 2025 for the preparation of the consolidated financial statements:
Amendments to HKAS 21
Lack of Exchangeability
The application of the amendments to a HKFRS Accounting Standard in the current year has no material impact on
the Group’s financial positions and performance for the current and prior years and/or on the disclosures set out in
these consolidated financial statements.
– 45 –
REVENUE AND SEGMENT INFORMATION
2025
RMB’000
24,217,279
1,788,701
26,005,980
Sale of goods
Licence fee income
2024
RMB’000
28,991,423
17,831
29,009,254
Information reported to executive directors , being collectively the chief operating decision maker, for the purposes
of resource allocation and assessment of segment performance focuses on types of goods delivered.
The Group’s reportable segments are as follows:
(a)
Finished drugs — research and development, manufacture and sale of pharmaceutical products and licence
fee income;
(b) Bulk products — manufacture and sale of vitamin C and antibiotic products in bulk powder form; and
(c)
Functional food and others — manufacture and sale of functional food products (including caffeine food
additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and
others.
Sale of goods
Revenue is recognised at a point of time upon control of the goods has transferred, being when the goods have
been delivered to the customer’s specific location. Following delivery, the customer bears the risks of obsolescence
and loss in relation to the goods. The normal credit term is 90 days upon delivery.
The transaction price received by the Group is recognised as a contract liability until the goods have been delivered
to the customer.
As at 31 December 2025, all outstanding sales contracts are expected to be fulfilled within one year.
Licence fee income
(i)
Revenue recognised at a point in time
The Group provides licence of its patented intellectual property or commercialisation rights to customers.
Licence fee income is recognised at a point in time when the customer obtains control of the intellectual
property. The consideration received comprises a fixed element (the upfront payment) and variable elements
(including but not limited to milestone payments and sales-based royalties).
For licence associated with customers’ right to use, upfront payment received is initially recorded as contract
liabilities and recognised as revenue only when customers have ability to use the licence and variable
consideration is recognised only to the extent that it is highly probable that such an inclusion will not result in
a significant revenue reversal in the future.
(ii) Revenue recognised over time
The Group enters into collaboration agreements to perform research and development activities and to grant
licences to customers. Revenue is recognised over time on a systematic basis that reflects the customer’s
receipt and consumption of the benefits, by reference to the progress towards complete satisfaction of the
relevant performance obligation.
– 46 –
Segment revenues and results
The following is an analysis of the Group’s revenue and results by operating and reportable segments.
For the year ended 31 December 2025:
Antibiotics
RMB’000
Functional
food and
others
RMB’000
Segment
total Eliminations Consolidated
RMB’000
RMB’000
RMB’000
2,230,639
4,036
–
1,426,333
142,375
–
1,765,279
54,965
–
24,217,279
201,376
1,788,701
–
(201,376)
–
24,217,279
–
1,788,701
20,583,729
2,234,675
1,568,708
1,820,244
26,207,356
(201,376)
26,005,980
3,870,645
191,782
184,426
276,056
4,522,909
Bulk products
Finished
drugs
RMB’000
Vitamin C
RMB’000
Segment revenue
Sale of goods
Inter-segment sales
Licence fee income
18,795,028
–
1,788,701
Total revenue
Segment profit
4,522,909
Unallocated income
Unallocated expenses
Share of results of associates
Share of results of joint ventures
Finance costs
487,457
(111,209)
(42,495)
(9,950)
(38,595)
Profit before tax
4,808,117
For the year ended 31 December 2024:
Finished
drugs
RMB’000
Vitamin C
RMB’000
Antibiotics
RMB’000
Functional
food and
others
RMB’000
Segment revenue
Sale of goods
Inter-segment sales
Licence fee income
23,718,326
–
17,831
1,994,256
36,478
–
1,588,907
183,575
–
1,689,934
174,697
–
28,991,423
394,750
17,831
–
(394,750)
–
28,991,423
–
17,831
Total revenue
23,736,157
2,030,734
1,772,482
1,864,631
29,404,004
(394,750)
29,009,254
Segment profit
4,827,585
211,279
299,175
305,291
5,643,330
Bulk products
Segment
total Eliminations Consolidated
RMB’000
RMB’000
RMB’000
5,643,330
Unallocated income
Unallocated expenses
Share of results of associates
Share of results of joint ventures
Finance costs
279,966
(211,423)
(45,922)
(43,552)
(43,673)
Profit before tax
5,578,726
– 47 –
Segment profit represents the profit earned by each segment without allocation of interest income, fair value
changes on structured bank deposits, fair value changes on financial assets measured at fair value through profit or
loss, central administrative expenses, share of results of associates and joint ventures and finance costs. This is the
measure reported to the executive directors for the purposes of resource allocation and performance assessment.
Inter-segment sales are charged at prevailing market rates.
The executive directors makes decisions according to operating results of each segment. No analysis of segment
asset and segment liability is presented as the executive directors do not regularly review such information for the
purposes of resource allocation and performance assessment. Therefore, only segment revenue and segment results
are presented.
Geographical information
Revenue from the external customers by geographical market (irrespective of the origin of the goods) based on the
location of customers is presented below:
Chinese Mainland
Other Asian regions
Europe
North America
Others
2025
RMB’000
2024
RMB’000
20,825,921
1,264,466
2,429,113
890,208
596,272
25,106,726
1,182,318
1,313,288
853,042
553,880
26,005,980
29,009,254
269,864
The Group’s operations are substantially based in the Chinese Mainland and majority of the Group’s non-current
assets are located in the Chinese Mainland. Therefore, no further analysis of geographical information is presented.
None of the Group’s customers contributed over 10% of the total revenue of the Group for both years.
– 48 –
PROFIT FOR THE YEAR
2025
RMB’000
2024
RMB’000
Staff costs, including directors’ and chief executive’s remuneration
— salaries, wages and other benefits
— contribution to retirement benefit schemes
— (reversal of) employee share-based compensation expenses (note a)
3,760,824
198,362
(65,948)
4,001,063
193,978
210,454
Total staff costs
3,893,238
4,405,495
Depreciation of property, plant and equipment
Depreciation of right-of-use assets
Depreciation of investment property
Amortisation of intangible assets
1,083,620
171,072
3,305
154,753
1,023,305
163,768
3,305
149,072
Total depreciation and amortisation
1,412,750
1,339,450
Auditor’s remuneration
Government grant income (included in other income)
(Reversal of) impairment losses recognised under ECL loss model
(included in other gains or losses)
Interest income on bank deposits and balances (included in other income)
Fair value (gain)/loss on financial assets measured at FVTPL
(included in other gains or losses)
Fair value gain on structured bank deposits (included in other gains or losses)
Loss on disposal of property, plant and equipment
(included in other gains or losses)
Net foreign exchange losses/(gains) (included in other gains or losses)
9,383
(210,300)
7,461
(128,772)
(9,971)
(195,872)
16,304
(232,497)
(296,263)
(39,241)
151,936
(47,470)
16,472
33,909
23,398
(19,789)
Profit for the year has been arrived at after charging/(crediting):
Notes:
(a)
The amount mainly included employee share-based compensation expenses of RMB11,344,000 (2024:
RMB12,052,000) in respect of share awards and share options granted by the Company and a reversal
of employee share-based compensation expenses of RMB77,292,000 (2024: recognition of expenses of
RMB198,319,000) in respect of share awards granted by the shareholders of the Company involving the
existing shares of the Company held by the shareholder.
(b) Cost of inventories recognised as an expense approximated cost of sales as shown in the consolidated income
statement for the years ended 31 December 2025 and 2024.
– 49 –
INCOME TAX EXPENSE
2025
RMB’000
2024
RMB’000
Current taxation:
— PRC Enterprise Income Tax
— PRC withholding tax on dividends distributed by subsidiaries
— Overseas taxation
746,409
141,000
28,644
1,191,896
253,000
6,095
Deferred taxation
916,053
15,674
1,450,991
(211,090)
931,727
1,239,901
No provision for Hong Kong Profits Tax has been made as the Group did not have any assessable profits arising in
or derived from Hong Kong for both years.
The standard tax rate of the Company’s PRC subsidiaries is 25% under the law of the PRC on Enterprise Income
Tax (the “EIT Law”) and implementation regulations of the EIT Law. Certain subsidiaries of the Company are
qualified as High and New Technology Enterprises, and they are subject to a preferential tax rate of 15% up to
2027.
Under the EIT Law, dividends distributed by a company established in the PRC to foreign investor with respect to
profits earned from 1 January 2008 onwards are subject to a withholding tax of 10%. The tax rate will be reduced
to 5% if such foreign investors meet certain conditions specified in the relevant tax regulations.
Taxation arising in other jurisdictions is calculated at the rates prevailing in relevant jurisdictions.
The Group is operating in certain jurisdictions where the Pillar Two Rules is effective. As the Group’s estimated
effective tax rates of such in-effect jurisdiction in which the Group operates is higher than 15%, after taking into
account the adjustments under the Global Anti-base Erosion Rules based on management’s best estimate, the
management of the Group considered the Group is not liable to top-up tax under the Pillar Two Rules.
6.
EARNINGS PER SHARE
The calculation of the basic and diluted earnings per share is as follows:
Profit attributable to owners of the Company (RMB’000)
Weighted average number of ordinary shares for
the purpose of basic earnings per share (in ’000)
Effect of dilutive potential ordinary shares:
Share options and share awards (in ’000)
Weighted average number of ordinary shares for
the purpose of diluted earnings per share (’000)
2025
RMB’000
2024
RMB’000
3,882,108
4,328,035
11,423,692
11,738,041
–
2
11,423,692
11,738,043
The weighted average number of ordinary shares for the calculation of basic earnings per share for both years has
been adjusted for the effects of the shares held by the trustee under the share award scheme of the Company.
– 50 –
DIVIDENDS
2025
RMB’000
2024
RMB’000
1,470,541
1,716,637
1,050,465
(23,669)
1,540,544
(23,366)
2,497,337
3,233,815
Dividends recognised as distribution during the year:
Interim dividend paid:
2025: HK14 cents (approximately RMB12.8 cents)
(2024: HK16 cents (approximately RMB14.7 cents)) per share
Final dividend paid:
2024: HK10 cents (approximately RMB9.1 cents)
(2023: HK14 cents (approximately RMB13 cents)) per share
Less: dividend for shares held by share award scheme
The final dividend for current year proposed after the end of the reporting period has not been recognised as a
liability at the end of the reporting period.
8.
TRADE RECEIVABLES
Trade receivables
Less: allowance for ECL
2025
RMB’000
2024
RMB’000
4,827,337
(48,470)
5,219,113
(58,441)
4,778,867
5,160,672
As at 1 January 2024, trade receivables (net of allowance under ECL model) from contracts with customers
amounted to RMB5,869,223,000.
The Group allows a general credit period of 90 days to its trade customers. The following is an ageing analysis of
trade receivables (net of allowance under ECL model) at the end of the reporting period presented based on the
invoice dates which approximated the respective revenue recognition dates:
0 to 90 days
91 to 180 days
181 to 365 days
More than 365 days
2025
RMB’000
2024
RMB’000
4,228,179
484,326
59,095
7,267
4,322,517
672,925
147,431
17,799
4,778,867
5,160,672
Trade receivables with aggregate carrying amount of RMB550,688,000 (2024: RMB838,155,000) are past due
as at the reporting date. Out of the past due balances, RMB66,362,000 (2024: RMB165,230,000) has been past
due 90 days or more and is not considered as in default because there has not been significant change in credit
quality and the amounts are still considered recoverable. The Group does not hold any collateral or other credit
enhancements over these balances nor does it have a legal right of offset against any amounts owed by the Group
to the counterparty.
– 51 –
DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES
Prepayments for raw materials and research and development expenses
Deposits paid for acquisition of property, plant and equipments and
right-of-use assets
Other taxes recoverable
Utility deposits
Others
Analysed as:
Current
Non-current
2025
RMB’000
2024
RMB’000
211,899
207,080
556,488
761,464
133,949
400,082
576,100
362,346
85,560
232,073
2,063,882
1,463,159
1,507,394
556,488
887,059
576,100
2,063,882
1,463,159
- BILLS RECEIVABLES
All bills receivables of the Group are with a maturity period of less than 365 days (2024: less than 365 days) and
not yet due at the end of the reporting period. The management considers the default risk is low based on historical
information, experience and forward looking information that is available without undue cost or effort.
- TRADE PAYABLES
The following is an ageing analysis of trade payables at the end of the reporting period presented based on the
invoice dates:
0 to 90 days
91 to 180 days
More than 180 days
The general credit period on purchases of goods is up to 90 days (2024: 90 days).
– 52 –
2025
RMB’000
2024
RMB’000
1,988,116
154,663
179,225
1,360,917
170,476
135,854
2,322,004
1,667,247
- OTHER PAYABLES
Other taxes payable
Payables arising from construction and acquisition of property,
plant and equipment
Deferred government grants
Salaries, wages and staff welfare payable
Selling expense payable
Research and development expense payable
Others
Analysed as:
Current
Non-current
2025
RMB’000
2024
RMB’000
340,226
196,717
1,015,294
797,190
520,626
2,455,746
296,742
471,528
1,033,790
661,956
509,439
2,925,497
189,807
632,395
5,897,352
6,149,601
5,334,111
563,241
5,741,793
407,808
5,897,352
6,149,601
- BILLS PAYABLES
All bills payables of the Group are aged within 365 days (2024: 365 days) and not yet due at the end of the
reporting period.
– 53 –
SUSTAINABLE DEVELOPMENT STRATEGIES
The Group will continue to pursue the development strategies of (i) active development of innovative
drug business; (ii) continuation of products internationalisation; and (iii) consolidation of leadership in
bulk drug business in order to achieve long-term sustainable growth.
CORPORATE GOVERNANCE
The Company has complied with all the code provisions in the Corporate Governance Code set out in
Appendix C1 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong
Limited throughout the year ended 31 December 2025.
REVIEW OF ANNUAL RESULTS
The consolidated financial statements of the Company and its subsidiaries for the year ended 31
December 2025 have been reviewed by the Audit Committee of the Company and audited by the
Company’s auditor.
CLOSURE OF REGISTER OF MEMBERS
The register of members of the Company will be closed from Thursday, 21 May 2026 to Thursday,
28 May 2026, both days inclusive, during which period no transfer of shares will be effected. The
record date for determining the eligibility of the shareholders to attend and vote at the annual general
meeting is Thursday, 28 May 2026. In order to determine the identity of members who are entitled to
attend and vote at the annual general meeting to be held on Thursday, 28 May 2026, all share transfer
documents accompanied by the relevant share certificates must be lodged with the Company’s share
registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong
Kong for registration not later than 4:30 p.m. on Wednesday, 20 May 2026.
The register of members of the Company will be closed from Friday, 26 June 2026 to Monday, 29
June 2026, both dates inclusive, during which period no transfer of shares will be effected. The record
date for entitlement to the proposed final dividend is Monday, 29 June 2026. In order to qualify for the
proposed final dividend, all share transfer documents accompanied by the relevant share certificates
must be lodged with the Company’s share registrar, Tricor Investor Services Limited, at 17/F, Far East
Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on Thursday,
25 June 2026.
– 54 –
PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES
During the year, the Company repurchased a total of 64,300,000 shares on The Stock Exchange of Hong
Kong Limited (the “Stock Exchange”) at a total consideration of approximately HK$300 million (before
expenses) and the repurchased shares were cancelled. The Board considered that such repurchases
were made for the benefit of shareholders with a view to enhancing earnings per share and maximising
shareholders’ returns. Details of the shares repurchased are as follows:
Month
Number
of shares
repurchased
Highest
purchase
price per
share
HK$
Lowest
purchase
price per
share
HK$
January
March
April
38,850,000
3,000,000
22,450,000
4.72
4.95
4.95
4.38
4.88
4.66
Total
64,300,000
Aggregate consideration
(before expenses)
HK$
RMB
(equivalent)
176,597,000
14,763,000
108,155,000
163,244,000
13,624,000
100,244,000
299,515,000
277,112,000
In October 2025, the trustee of the Company’s share award scheme adopted on 20 August 2018 (the
“2018 Share Award Scheme”) purchased a total of 17,000,000 shares of the Company on the Stock
Exchange to be held on trust for a total consideration of approximately HK$153,787,000 (equivalent
to approximately RMB140,401,000), pursuant to the terms and conditions of the 2018 Share Award
Scheme.
Saved as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed
any of the Company’s securities listed on the Stock Exchange during the year.
By order of the Board
CAI Dong Chen
Chairman
Hong Kong, 25 March 2026
As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI
Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing,
Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and
Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk
Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.
– 55 –